Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
40.3 /100
Rank 45 out of 131 Industries -
Advance/Decline
127/207
-
No. of Companies334
-
Avg. Market Cap15,151
-
Price to Earning Ratio4.50
-
Price to Earning Growth Ratio1.05
-
Price to Book Ratio20.91
-
Return on Equity13.56
-
Return on Capital Employed-
-
Return on Assets7.67
-
Dividend yield 1 year %0.72 %
-
Net Profit Growth Annual YoY %-66.80 %
-
Net Profit Growth Qtr YoY %-18.24 %
-
Net Profit Growth Qtr QoQ %154.89 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
467,119.8
|
264.3
|
L
 -0.3%
H
262.6
266
|
L
 0.1%
H
261.2
269.4
|
L
 -0.1%
H
246.8
269.4
|
L
 12.5%
H
233.7
269.4
|
L
 20.2%
H
190.8
269.4
|
L
 73.1%
H
135.9
269.4
|
L
 146.9%
H
106.9
269.4
|
L
 306.8%
H
55.1
269.4
|
| Adc Therapeutics SA |
|
162.1
|
1.3
|
L
 -1.6%
H
1.2
1.3
|
L
 19.8%
H
1.0
1.3
|
L
 32.3%
H
1.0
1.4
|
L
 18.7%
H
0.9
1.5
|
L
 -64.3%
H
0.8
5.0
|
L
 76.4%
H
0.4
6.0
|
L
 -95.5%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
6,885.8
|
19.8
|
L
 -0.2%
H
19.3
20
|
L
 8.2%
H
18.1
21.2
|
L
 11.2%
H
16.6
21.2
|
L
 14.5%
H
16.5
21.2
|
L
 103.6%
H
9.5
21.2
|
L
 371.8%
H
3.4
21.2
|
L
 272.3%
H
1.2
21.2
|
L
 -25.4%
H
1.2
27.3
|
| Annovis Bio Inc |
|
55.9
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 19.1%
H
1.1
1.4
|
L
 -25.1%
H
1.0
1.9
|
L
 -22.9%
H
1.0
2.2
|
L
 -40.2%
H
1.0
5.5
|
L
 -86.8%
H
1.0
22.5
|
L
 -96.2%
H
1.0
39.7
|
L
H
1.0
132
|
| Bristol-Myers Squibb |
|
128,405.0
|
62.9
|
L
 2.2%
H
61.4
62.9
|
L
 0.0%
H
60.6
63.4
|
L
 -6.6%
H
60.6
68.2
|
L
 14.3%
H
55.0
68.6
|
L
 42.4%
H
42.5
68.6
|
L
 6.7%
H
39.4
68.6
|
L
 4.4%
H
39.4
81.4
|
L
 11.3%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
348.1
|
6.8
|
L
 0.3%
H
6.7
6.8
|
L
 -3.3%
H
6.5
7.0
|
L
 31.1%
H
5.2
7.1
|
L
 -19.5%
H
4.4
8.6
|
L
 -18.1%
H
4.4
14.1
|
L
 108.3%
H
1.4
15.1
|
L
 -87.0%
H
1.4
55.4
|
L
 -76.1%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
98,652.9
|
49.2
|
L
 -0.8%
H
49
49.5
|
L
 -3.6%
H
49
51.3
|
L
 -4.9%
H
47.9
52.2
|
L
 -3.6%
H
47.9
55.8
|
L
 22.6%
H
39.3
61.7
|
L
 31.6%
H
31.7
61.7
|
L
 26.0%
H
28.5
61.7
|
L
 11.4%
H
28.5
61.7
|
| Johnson & Johnson |
|
653,612.7
|
271.2
|
L
 0.2%
H
269.3
272.3
|
L
 0.4%
H
265.0
275.2
|
L
 -0.2%
H
260.7
281.1
|
L
 12.5%
H
240.9
281.1
|
L
 53.5%
H
175.9
281.1
|
L
 69.0%
H
140.7
281.1
|
L
 65.0%
H
140.7
281.1
|
L
 128.3%
H
109.2
281.1
|
| Eli Lilly |
|
1,054,885.4
|
1,183.5
|
L
 0.1%
H
1160.8
1190
|
L
 2.7%
H
1134.4
1197.8
|
L
 -5.1%
H
1113.3
1264.7
|
L
 5.9%
H
1109.2
1292.7
|
L
 59.5%
H
712.1
1292.7
|
L
 115.0%
H
516.6
1292.7
|
L
 410.8%
H
220.2
1292.7
|
L
 1358.2%
H
64.2
1292.7
|
| Merck & Company |
|
367,065.8
|
148.8
|
L
 0.5%
H
147.5
150.0
|
L
 1.1%
H
145.6
153.6
|
L
 -1.3%
H
142.3
156.9
|
L
 23.4%
H
120.2
156.9
|
L
 86.8%
H
77.6
156.9
|
L
 39.9%
H
73.3
156.9
|
L
 102.1%
H
71.5
156.9
|
L
 147.6%
H
50.4
156.9
|
| Novo Nordisk (ADR) |
|
171,371.3
|
38.8
|
L
 0.5%
H
38.4
38.8
|
L
 -10.2%
H
37.9
43.5
|
L
 -17.3%
H
37.9
48.7
|
L
 -18.2%
H
37.9
52.1
|
L
 -34.0%
H
35.1
64.2
|
L
 -57.5%
H
35.1
148.2
|
L
 -22.9%
H
35.1
148.2
|
L
 72.9%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
276,478.0
|
145.5
|
L
 1.3%
H
144
145.5
|
L
 3.2%
H
139.6
145.5
|
L
 -8.0%
H
137
164.5
|
L
 -5%
H
137
164.5
|
L
 18.3%
H
121.6
170.5
|
L
 43.8%
H
92.2
170.5
|
L
 75.4%
H
74.1
170.5
|
L
 101.9%
H
59.2
170.5
|
| Organon & Co. |
|
3,605.6
|
13.7
|
L
 0.1%
H
13.7
13.7
|
L
 0.3%
H
13.7
13.8
|
L
 -0.2%
H
13.6
13.8
|
L
 1.9%
H
13.5
13.8
|
L
 31.9%
H
5.7
13.8
|
L
 -24.8%
H
5.7
23.1
|
L
 -59.2%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,208.1
|
46.6
|
L
 2.1%
H
45.0
46.7
|
L
 0.3%
H
44.5
47.8
|
L
 -10.4%
H
44.5
54.0
|
L
 -1.5%
H
44.5
56.0
|
L
 -26.3%
H
42.6
71.1
|
L
 -19.5%
H
42.6
90.0
|
L
 -16.6%
H
42.6
90.0
|
L
 -4.3%
H
26.3
90.0
|
| Pfizer |
|
163,409.6
|
28.7
|
L
 0.9%
H
28.2
28.7
|
L
 3.7%
H
27.3
28.9
|
L
 2.5%
H
27.2
29.2
|
L
 19.3%
H
23.6
29.2
|
L
 19.0%
H
23.6
29.2
|
L
 -12.3%
H
20.9
34.1
|
L
 -34.8%
H
20.9
61.7
|
L
 -11.7%
H
20.9
61.7
|
| Perrigo Co PLC |
|
2,139.8
|
15.4
|
L
 5.0%
H
14.2
15.7
|
L
 14.4%
H
13.2
15.7
|
L
 8.1%
H
13.2
15.7
|
L
 58.0%
H
9.6
15.7
|
L
 -27.9%
H
9.2
22.7
|
L
 -52.2%
H
9.2
34.6
|
L
 -64.1%
H
9.2
50.9
|
L
 -84.2%
H
9.2
98.2
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,204.1
|
12.3
|
L
 -0.4%
H
12.2
12.4
|
L
 0.5%
H
12.1
12.7
|
L
 0.3%
H
11.5
12.7
|
L
 -16.4%
H
11.4
15.7
|
L
 -15.2%
H
11.4
15.7
|
L
 -7.9%
H
11.4
74.9
|
L
 -5.6%
H
9.6
74.9
|
L
 27.9%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
60,229.5
|
18.9
|
L
 1.5%
H
18.8
18.9
|
L
 -1%
H
18.5
19.0
|
L
 3.4%
H
18.0
19.1
|
L
 20.0%
H
15.6
19.1
|
L
 26.1%
H
13.0
19.1
|
L
 19.1%
H
12.6
19.1
|
L
 11.7%
H
12.3
19.1
|
L
 -20.8%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
45,668.0
|
39.2
|
L
 -2.6%
H
38.9
40.3
|
L
H
38.4
40.8
|
L
 6.1%
H
35.4
40.8
|
L
 14.5%
H
29.6
40.8
|
L
 103.4%
H
18.2
40.8
|
L
 278.6%
H
8.1
40.8
|
L
 337.9%
H
6.8
40.8
|
L
 -23.9%
H
6.1
51.2
|
| Zoetis (Class A) |
|
29,359.5
|
71.1
|
L
 1.1%
H
69.5
71.1
|
L
 -2.7%
H
69.5
73.6
|
L
 -7.9%
H
69.5
78.8
|
L
 -9.1%
H
69.5
80.2
|
L
 -49.9%
H
69.5
148.8
|
L
 -59.8%
H
69.5
201.9
|
L
 -65.3%
H
69.5
249.3
|
L
 37.9%
H
46.9
249.3
|
| Biohaven Ltd |
|
1,962.1
|
13.0
|
L
 -1.5%
H
12.8
13.4
|
L
 -6.5%
H
12.8
15.0
|
L
 -5.0%
H
11.9
18.2
|
L
 -13.2%
H
11.9
18.2
|
L
 -5.5%
H
7.5
18.6
|
L
 -23.3%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
40,722.0
|
9.3
|
L
 0.4%
H
9.1
9.3
|
L
 -1.1%
H
9.1
9.4
|
L
 -8.9%
H
9.1
10.3
|
L
 0.3%
H
9.1
10.3
|
L
 4.4%
H
8.7
11.3
|
L
 13.6%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Abeona Therapeutics Inc |
|
308.8
|
5.4
|
L
 -0.6%
H
5.3
5.5
|
L
 -3.4%
H
5.3
5.9
|
L
 -10.9%
H
5.2
6.3
|
L
 -3.9%
H
5.2
7.7
|
L
 -2.7%
H
4
7.7
|
L
 42.5%
H
3.1
9.0
|
L
 -81.7%
H
2.2
29.9
|
L
 -96.6%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
5,592.1
|
84.5
|
L
 -1.2%
H
84
86.5
|
L
 -13.6%
H
82.7
98.3
|
L
 -17.5%
H
82.7
106.9
|
L
 2.9%
H
80.7
115.5
|
L
 453.1%
H
14.9
115.5
|
L
 250.2%
H
2.2
115.5
|
L
 136.2%
H
2.2
115.5
|
L
 -86.3%
H
2.2
648
|
| Acumen Pharma Inc |
|
162.0
|
2.2
|
L
H
2.2
2.3
|
L
 -12.8%
H
2.2
2.7
|
L
 -27.3%
H
2.2
3.3
|
L
 -3.0%
H
2.1
3.3
|
L
 76.4%
H
1.3
3.6
|
L
 -49.7%
H
0.9
5.1
|
L
 -86.1%
H
0.9
16.3
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
960.8
|
4.9
|
L
 -0.6%
H
4.8
4.9
|
L
 -4.3%
H
4.8
5.1
|
L
 -6.7%
H
4.8
5.3
|
L
 8.7%
H
4.3
5.5
|
L
 8.0%
H
3.5
5.5
|
L
 151.3%
H
1.7
5.5
|
L
 5.0%
H
1.7
6.5
|
L
 22.5%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
30.1
|
1.1
|
L
 3.7%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 34.5%
H
0.7
1.2
|
L
 -15.0%
H
0.7
2.2
|
L
 -65.0%
H
0.7
3.4
|
L
 28.4%
H
0.4
5.5
|
L
 -95.4%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,563.3
|
20.7
|
L
 -6.8%
H
20.6
22.2
|
L
 -24.7%
H
20.6
27.5
|
L
 -30.3%
H
20.6
30.8
|
L
 -11.5%
H
20.6
31.0
|
L
 -2.7%
H
19.7
31.0
|
L
 -12.2%
H
13.4
32.6
|
L
 22.1%
H
12.2
33.9
|
L
 -40.9%
H
12.2
58.7
|
| Adicet Bio Inc |
|
84.4
|
9.0
|
L
 9.1%
H
8.3
9.1
|
L
 0.1%
H
7.9
9.4
|
L
 1.4%
H
7.9
10.0
|
L
 9.3%
H
7.4
10.0
|
L
 -34.1%
H
6.0
17.4
|
L
 -61.4%
H
6.0
60.3
|
L
 -92.6%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
775.9
|
7.5
|
L
 -3.7%
H
7.5
8.0
|
L
 -4.7%
H
7.5
8.4
|
L
 -5.0%
H
7.0
8.6
|
L
 42.3%
H
5.2
8.6
|
L
 144.8%
H
2.6
8.6
|
L
 72.9%
H
1.8
8.6
|
L
 -19.5%
H
1.8
10.3
|
L
 -99.3%
H
1.8
2035
|
| AC Immune SA |
|
250.6
|
2.5
|
L
 -5.3%
H
2.5
2.7
|
L
 -6.0%
H
2.5
2.9
|
L
 -11.9%
H
2.5
3
|
L
 -0.8%
H
2.1
3
|
L
 -7.7%
H
2.1
4
|
L
 -15.2%
H
1.4
5.1
|
L
 -63.5%
H
1.4
8.1
|
L
 -83.9%
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
758.1
|
5.2
|
L
 -4.3%
H
5.1
5.5
|
L
 -4.6%
H
5.0
5.8
|
L
 -18.4%
H
5.0
6.6
|
L
 7.5%
H
4.8
6.6
|
L
 175.4%
H
1.7
6.6
|
L
 -22.6%
H
0.6
7.0
|
L
 -71.5%
H
0.6
20.0
|
L
 -79.3%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
90.0
|
2.1
|
L
 -0.9%
H
2.1
2.1
|
L
 23.5%
H
1.7
2.2
|
L
 -4.6%
H
1.7
2.3
|
L
 29.6%
H
1.4
2.4
|
L
 34.6%
H
1.3
3.6
|
L
 -77.5%
H
1.1
11.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
20.0
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 11.3%
H
1.0
1.5
|
L
 28.3%
H
0.7
1.6
|
L
 76.1%
H
0.4
1.6
|
L
 -94.4%
H
0.4
21.6
|
L
 -98.4%
H
0.4
115
|
| Grace Therapeutics Inc |
|
44.6
|
2.1
|
L
 -1.9%
H
2.1
2.1
|
L
 -0.5%
H
2.1
2.2
|
L
 -2.8%
H
2.1
2.5
|
L
 -9.0%
H
1.9
2.6
|
L
 -31.6%
H
1.8
5.2
|
L
 19.8%
H
1.7
5.2
|
L
 -84.4%
H
1.7
14.3
|
L
 -97.7%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
5.8
|
1.4
|
L
H
1.4
1.4
|
L
 -2.2%
H
1.3
1.4
|
L
 -2.9%
H
1.3
1.5
|
L
 -7.5%
H
1.3
1.9
|
L
 -67.2%
H
1.3
8.3
|
L
 -95.6%
H
1.3
176.4
|
L
 -98.4%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
12.4
|
4.2
|
L
 -5.0%
H
4.1
4.6
|
L
 -19%
H
3.8
5.2
|
L
 -21.9%
H
3.8
7.2
|
L
 70.2%
H
2.4
7.2
|
L
 -51.5%
H
1.3
10.8
|
L
 -93.3%
H
1.3
107.5
|
L
 -99.9%
H
1.3
3125
|
L
H
1.3
5900
|
| Agios Pharma Inc |
|
1,945.1
|
32.6
|
L
 -1.0%
H
32.5
33.3
|
L
 -3.1%
H
31.4
35.4
|
L
 -0.2%
H
31.4
35.4
|
L
 -10.2%
H
29.2
44.1
|
L
 -12.7%
H
22.2
46
|
L
 32.8%
H
19.8
62.6
|
L
 -31.4%
H
16.8
62.6
|
L
 -38.6%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
346.9
|
85.7
|
L
 -1.6%
H
85.6
88.1
|
L
 -7.5%
H
82.9
94.1
|
L
 -19.7%
H
82.9
110.2
|
L
 -0.6%
H
82.9
110.2
|
L
 404.1%
H
15.5
110.2
|
L
 622.5%
H
8.4
110.2
|
L
 -55.3%
H
2.7
212.5
|
L
 -47.2%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
249.4
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
H
0.9
1
|
L
H
0.9
1.1
|
L
 -15.1%
H
0.8
1.5
|
L
 -67.5%
H
0.8
3.2
|
L
 -23.7%
H
0.8
4.1
|
L
 -68.5%
H
0.2
4.1
|
L
 -90.2%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
34.4
|
5.5
|
L
 -0.7%
H
5.5
5.8
|
L
 6.6%
H
5.0
6.3
|
L
 -20.5%
H
4.8
7.7
|
L
 -1.3%
H
4.0
7.8
|
L
 -48.7%
H
4.0
13.7
|
L
 -71.0%
H
3.8
46.3
|
L
 -98.6%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
6,853.1
|
40.9
|
L
 0.2%
H
40.5
41.1
|
L
 -12.6%
H
40.5
46.5
|
L
 -16.4%
H
40.5
49.6
|
L
 -19.0%
H
40.5
55.7
|
L
 46.9%
H
27.0
55.7
|
L
 40.8%
H
22.0
55.7
|
L
 27.3%
H
21.2
55.7
|
L
 -17.6%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
16.4
|
1.0
|
L
 -5.5%
H
1.0
1.1
|
L
 -11.2%
H
1.0
1.2
|
L
 -25.9%
H
1.0
1.5
|
L
 -20.8%
H
1.0
1.6
|
L
 -36.8%
H
0.8
1.8
|
L
 -93.2%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
34,249.8
|
256.0
|
L
 2.6%
H
247.5
256.7
|
L
 4.3%
H
238.0
256.7
|
L
 8.5%
H
223.6
272.1
|
L
 -13.0%
H
197.8
380
|
L
 -44.2%
H
197.8
495.6
|
L
 49.2%
H
142.0
495.6
|
L
 36.6%
H
117.6
495.6
|
L
 238.7%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
64.7
|
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 -5.1%
H
0.7
0.8
|
L
 -6.3%
H
0.7
1.0
|
L
 -25.7%
H
0.7
1.1
|
L
 -37.0%
H
0.7
2.2
|
L
 -51.0%
H
0.7
7.4
|
L
 -96.6%
H
0.7
21.8
|
L
H
0.7
309.6
|
| Alzamend Neuro Inc |
|
8.8
|
1.8
|
L
 0.6%
H
1.8
1.9
|
L
 -0.5%
H
1.8
2.0
|
L
 18.1%
H
1.5
2.0
|
L
 33.6%
H
1.1
2.0
|
L
 -23.1%
H
0.8
2.7
|
L
 -99.4%
H
0.8
351
|
L
 -99.9%
H
0.8
4819.5
|
L
H
0.8
45292.5
|
| Amylyx Pharma Inc |
|
3,763.7
|
29.5
|
L
 -2.2%
H
29.5
30.7
|
L
 -13.1%
H
29.5
34.2
|
L
 -22.7%
H
29.5
38.9
|
L
 73.5%
H
16.5
41.1
|
L
 112.5%
H
10.8
41.1
|
L
 59.6%
H
1.6
41.1
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,111.5
|
26.1
|
L
 -0.5%
H
25.7
26.6
|
L
 9.7%
H
23.5
26.6
|
L
 21.4%
H
21.4
26.6
|
L
 24.3%
H
18.4
26.6
|
L
 -2.8%
H
16.6
29.5
|
L
 -42.6%
H
16.6
65.9
|
L
 39.7%
H
16.6
67.7
|
L
 30.2%
H
12.1
67.7
|
| Annexon Inc |
|
690.1
|
3.6
|
L
 -4.2%
H
3.6
3.9
|
L
 -12.7%
H
3.6
4.4
|
L
 -28.1%
H
3.6
5.3
|
L
 -31.3%
H
3.6
6.6
|
L
 29.1%
H
2.5
7.2
|
L
 51.0%
H
1.3
8.4
|
L
 -82.6%
H
1.3
22.5
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
184.2
|
4.9
|
L
 -0.2%
H
4.7
5.0
|
L
 -0.4%
H
4.7
5.3
|
L
 -13.3%
H
4.7
6.2
|
L
 -6.2%
H
4.1
7.2
|
L
 281.3%
H
1
7.2
|
L
 -64.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Niki BioSolutions Inc |
|
3.9
|
4.8
|
L
 -4.2%
H
4.7
5.1
|
L
 -9.5%
H
4.5
5.2
|
L
 -40.6%
H
4.5
9.7
|
L
 -41.5%
H
4.5
12.2
|
L
 -73.1%
H
4.5
25.9
|
L
 -78.0%
H
4.5
174.9
|
L
 -98.2%
H
4.5
272.0
|
L
H
4.5
3328
|
| Aprea Therapeutics Inc |
|
9.6
|
0.8
|
L
 -2.6%
H
0.7
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 -5%
H
0.7
1.2
|
L
 -6.2%
H
0.6
1.2
|
L
 -46.5%
H
0.6
1.7
|
L
 -81.7%
H
0.6
8.9
|
L
 -99.2%
H
0.6
113.4
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
587.4
|
4.7
|
L
 -2.9%
H
4.7
4.9
|
L
 0.4%
H
4.5
5.1
|
L
 -2.5%
H
4.5
5.5
|
L
 -6.2%
H
3.6
5.5
|
L
 -13.7%
H
2.9
7.6
|
L
 196.2%
H
1.3
7.6
|
L
 8.1%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
393.7
|
13.9
|
L
 -1.9%
H
13.3
14.5
|
L
 -18.2%
H
13.3
17.8
|
L
 -3.4%
H
13.1
18.0
|
L
 97.6%
H
5.5
18.0
|
L
 -32.3%
H
5.5
24.2
|
L
 -49.2%
H
5.5
45
|
L
 -72.7%
H
5.5
51.6
|
L
 -57.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
883.0
|
3.4
|
L
 -0.9%
H
3.4
3.5
|
L
 1.2%
H
3.3
3.6
|
L
 -8.6%
H
3.3
3.9
|
L
 -44.8%
H
3.3
6.4
|
L
 -44.4%
H
3.3
8.4
|
L
 -13.4%
H
3.2
10.1
|
L
 161.1%
H
0.5
10.1
|
L
 -72.2%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,383.6
|
26.9
|
L
 2.5%
H
25.8
27.1
|
L
 1.7%
H
25.1
28.3
|
L
 8.6%
H
23.1
28.3
|
L
 -1.6%
H
23.1
29.8
|
L
 55.6%
H
16.6
31.8
|
L
 400.4%
H
1.8
31.8
|
L
 16.1%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.5
|
4.5
|
L
 -12.2%
H
4.4
4.9
|
L
 14.4%
H
3.9
15.7
|
L
 -26.8%
H
3.5
15.7
|
L
 -56.5%
H
3.5
15.7
|
L
 -97.1%
H
3.5
179.2
|
L
 -98.2%
H
3.5
772.2
|
L
 -99.8%
H
3.5
3207.6
|
L
H
3.5
419904
|
| Assembly Biosciences Inc |
|
481.9
|
23.7
|
L
 0.0%
H
23.4
24.3
|
L
 -6.6%
H
23.2
25.9
|
L
 -32.9%
H
23.2
37.0
|
L
 -7.6%
H
23.2
37.0
|
L
 -7.8%
H
21.8
39.7
|
L
 113.4%
H
7.7
39.7
|
L
 -41.5%
H
7.7
42.6
|
L
 -75.4%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
447.7
|
2.9
|
L
 -1.0%
H
2.9
3.0
|
L
 -9.9%
H
2.9
3.3
|
L
 -24.9%
H
2.9
4.4
|
L
 -58.6%
H
2.9
7.5
|
L
 -73.7%
H
2.9
14.5
|
L
 224.4%
H
0.9
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ETHZilla Corp |
|
66.5
|
5.0
|
L
 -3.3%
H
5.0
5.2
|
L
 5%
H
4.5
5.2
|
L
 -16.4%
H
4.3
6.2
|
L
 -0.6%
H
4.3
7.2
|
L
 -79.3%
H
1.8
27.1
|
L
 -95.4%
H
1.8
177.5
|
L
 -100.0%
H
1.8
26448
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
19.0
|
1.9
|
L
 -7.3%
H
1.9
2.1
|
L
 -20.8%
H
1.9
2.4
|
L
 -28.0%
H
1.9
2.7
|
L
 8.6%
H
1.7
3.0
|
L
 -84.7%
H
1.7
19.4
|
L
 -84.7%
H
1.7
34.7
|
L
 -96.3%
H
1.7
53.0
|
L
 -99.5%
H
1.7
468
|
| Atara Biotherapeutics Inc |
|
88.4
|
8.8
|
L
 3.2%
H
8.5
9.0
|
L
 -9.3%
H
8.3
10.2
|
L
 -6.9%
H
8.3
11.3
|
L
 -16.5%
H
7.4
12
|
L
 -38.2%
H
3.9
19.1
|
L
 -80.3%
H
0.4
45.8
|
L
 -97.9%
H
0.4
501
|
L
 -98.2%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
414.7
|
5.2
|
L
H
5.0
5.2
|
L
 -1.7%
H
5.0
5.7
|
L
 -6.2%
H
5.0
5.9
|
L
 15.4%
H
3.8
5.9
|
L
 78.3%
H
2.8
6.5
|
L
 61.6%
H
2.5
6.5
|
L
 -83.9%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
829.7
|
15.5
|
L
 -1.6%
H
15
15.8
|
L
 -7.3%
H
14.6
16.9
|
L
 -19.7%
H
14.6
20.9
|
L
 -14.8%
H
14.6
21.0
|
L
 33.4%
H
10.7
24.3
|
L
 12791.7%
H
0.0
34.5
|
L
 -46.5%
H
0.0
34.5
|
L
 -73.7%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
24.8
|
2.3
|
L
 -1.3%
H
2.2
2.3
|
L
 14%
H
2
2.4
|
L
 -1.3%
H
1.9
2.4
|
L
 4.1%
H
1.9
2.5
|
L
 10.7%
H
1.7
3.1
|
L
 47.1%
H
1.0
3.5
|
L
 -96.2%
H
1.0
65.8
|
L
 -100.0%
H
1.0
311200
|
| Adagene Inc (ADR) |
|
196.7
|
2.9
|
L
 -1.7%
H
2.9
3.2
|
L
 -13.1%
H
2.8
3.5
|
L
 -24.9%
H
2.8
4.1
|
L
 -31.1%
H
2.8
4.9
|
L
 44.3%
H
1.3
4.9
|
L
 127.1%
H
1.2
4.9
|
L
 -79.4%
H
0.9
14.5
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
4.6
|
3.7
|
L
 5.5%
H
3.5
3.8
|
L
 8.6%
H
3.2
3.8
|
L
 -9.9%
H
3.1
4.4
|
L
 -39.2%
H
3.1
6.5
|
L
 -60.5%
H
3.1
12.0
|
L
 -50.1%
H
3.1
27.9
|
L
 -98.1%
H
3.1
189
|
L
H
3.1
750.4
|
| Amarin Corp (ADR) |
|
278.8
|
13.2
|
L
 -1.7%
H
13
13.4
|
L
 -4.8%
H
13
13.9
|
L
 -4.6%
H
13
15.2
|
L
 -19.6%
H
13
17.0
|
L
 -14.5%
H
13.0
20.9
|
L
 1319.4%
H
0.4
20.9
|
L
 144.4%
H
0.4
20.9
|
L
 349.0%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
13,850.3
|
225.6
|
L
 -2.2%
H
224.3
230.4
|
L
 -5.6%
H
220.2
243.7
|
L
 -10.5%
H
220.2
272.5
|
L
 -5.2%
H
220.2
282.2
|
L
 16.7%
H
186.1
282.2
|
L
 137.3%
H
85.3
282.2
|
L
 37.6%
H
61.6
282.2
|
L
 1049.3%
H
17.2
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
66.8
|
3.7
|
L
 -2.7%
H
3.6
3.7
|
L
 -2.1%
H
3.5
4
|
L
 -19.7%
H
3.5
5.0
|
L
 -27.5%
H
3.5
5.9
|
L
 -16.4%
H
2.7
5.9
|
L
 38.5%
H
1
7
|
L
 -71.3%
H
1
13.8
|
L
 -92.7%
H
1
51.5
|
| Autolus Therapeutics PLC (ADR) |
|
495.1
|
1.9
|
L
 -2.6%
H
1.9
1.9
|
L
 -3.1%
H
1.9
2.1
|
L
 -20.5%
H
1.8
2.5
|
L
 17.0%
H
1.4
2.6
|
L
 19.2%
H
1.2
2.6
|
L
 -20.5%
H
1.1
7.5
|
L
 -70.4%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
516,492.5
|
166.6
|
L
 1.2%
H
164.6
166.8
|
L
 0.3%
H
162.9
169.4
|
L
 -0.1%
H
156.7
170.2
|
L
 -9.0%
H
153.4
196.4
|
L
 -11.6%
H
153.4
212.7
|
L
 -11.6%
H
153.4
212.7
|
L
 -11.6%
H
153.4
212.7
|
L
 -11.6%
H
153.4
212.7
|
| Biofrontera Inc |
|
17.5
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 -4.8%
H
1.1
1.3
|
L
 -19.2%
H
1.1
1.7
|
L
 18%
H
0.9
1.7
|
L
 22.9%
H
0.6
1.7
|
L
 -87.2%
H
0.5
9.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
33,628.8
|
227.6
|
L
 0.6%
H
223.8
228.9
|
L
 3.9%
H
214.6
229.2
|
L
 4.4%
H
208.9
229.2
|
L
 14.0%
H
186.0
229.2
|
L
 65.3%
H
135.4
229.2
|
L
 -11.7%
H
110.0
269.4
|
L
 -22.0%
H
110.0
319.8
|
L
 -21.0%
H
110.0
468.6
|
| Biomea Fusion Inc |
|
95.7
|
1.3
|
L
 -11.4%
H
1.3
1.5
|
L
 -26.3%
H
1.3
1.9
|
L
 -17.0%
H
1.3
2.1
|
L
 5.6%
H
1.1
2.1
|
L
 -35.9%
H
0.9
3.0
|
L
 -91.0%
H
0.9
22.7
|
L
 -87.4%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
6.9
|
3.6
|
L
 -0.3%
H
3.6
3.7
|
L
 7.2%
H
3.1
3.9
|
L
 -4.3%
H
3.1
4.4
|
L
 -15.2%
H
3.1
4.5
|
L
 -38.0%
H
3.1
7.2
|
L
 -82.8%
H
3.1
31.2
|
L
 -98.6%
H
3.1
283.6
|
L
H
3.1
861.4
|
| Blue Water Biotech Inc |
|
18.4
|
1.0
|
L
 13.2%
H
1
1.4
|
L
 56.1%
H
0.6
1.4
|
L
 56.1%
H
0.6
1.4
|
L
 3%
H
0.6
1.4
|
L
 -67.5%
H
0.1
6.7
|
L
 80.7%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
32.1
|
0.8
|
L
 8.3%
H
0.7
0.8
|
L
 9.9%
H
0.7
0.8
|
L
 9.9%
H
0.6
0.8
|
L
 -52.4%
H
0.6
1.9
|
L
 -53.9%
H
0.6
2.4
|
L
 -1.3%
H
0.6
4
|
L
 -94.9%
H
0.5
18.0
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
257.6
|
3.7
|
L
 -1.3%
H
3.7
3.7
|
L
H
3.6
4.0
|
L
 -15.0%
H
3.6
4.5
|
L
 -7.1%
H
3.6
4.5
|
L
 -51.5%
H
3.6
9.2
|
L
 -81.7%
H
3.6
28.7
|
L
 -91.4%
H
3.6
62.1
|
L
H
3.6
62.1
|
| Biodexa Pharma PLC (ADR) |
|
0.7
|
0.7
|
L
H
0.7
0.7
|
L
 -15%
H
0.6
0.8
|
L
 -43.3%
H
0.6
1.6
|
L
 -74.0%
H
0.6
3.1
|
L
 -97.9%
H
0.6
59.4
|
L
 -100.0%
H
0.6
275312.5
|
L
 -100.0%
H
0.6
95995000
|
L
 -100.0%
H
0.6
9125000000.0
|
| BeiGene Ltd (ADR) |
|
38,440.0
|
360.9
|
L
 0.2%
H
358.5
365
|
L
 2.1%
H
348.8
368.3
|
L
 -3.0%
H
337.0
380
|
L
 30.2%
H
272.8
380
|
L
 9.4%
H
254.0
385.2
|
L
 89.3%
H
127.0
385.2
|
L
 -4.9%
H
118.2
392.3
|
L
 1083.5%
H
26.4
426.6
|
| Bioline Rx Ltd (ADR) |
|
12.6
|
2.6
|
L
 3.2%
H
2.5
2.6
|
L
 2.8%
H
2.4
2.6
|
L
 -13.3%
H
2.4
3.0
|
L
 -22.9%
H
2.4
3.3
|
L
 -31.2%
H
2.2
4.6
|
L
 -96.9%
H
0.1
84.8
|
L
 -97.8%
H
0.1
126
|
L
 -99.7%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,738.7
|
167.3
|
L
 -1.3%
H
167.1
172
|
L
 -1.8%
H
165.6
178.4
|
L
 5.3%
H
150.2
198.6
|
L
 11.0%
H
141.0
198.6
|
L
 139.7%
H
68.2
200
|
L
 431.2%
H
28.5
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
19.8
|
3.7
|
L
H
3.7
3.7
|
L
 -1.9%
H
3.7
3.8
|
L
 -7.6%
H
3.7
4
|
L
 -18.7%
H
3.2
4.6
|
L
 -68.1%
H
3.2
21.4
|
L
 241.1%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
486.0
|
8.4
|
L
 -2.5%
H
8.3
8.7
|
L
 -11.3%
H
8.3
9.5
|
L
 22.9%
H
7.3
11
|
L
 -71.7%
H
3.0
30.9
|
L
 35.1%
H
3.0
40.4
|
L
 52%
H
2.7
40.4
|
L
 59.8%
H
2.6
40.4
|
L
 -76.2%
H
0.9
42.5
|
| Crescent Biopharma Inc |
|
-
|
14.0
|
L
 -1.8%
H
13.7
14.5
|
L
 -16.6%
H
13.4
17.9
|
L
 -17.6%
H
13.4
22.3
|
L
 -19.4%
H
13.4
22.3
|
L
 7.8%
H
8.7
27.4
|
L
 89.8%
H
4.8
27.4
|
L
 20.9%
H
0.9
27.4
|
L
 -70.8%
H
0.9
90.3
|
| Cullinan Oncology Inc |
|
953.1
|
14.8
|
L
 -4.1%
H
14.7
15.6
|
L
 -30.7%
H
14.7
21.9
|
L
 -32.1%
H
14.7
23.2
|
L
 -16.1%
H
14.7
23.2
|
L
 145.6%
H
5.7
23.2
|
L
 56.1%
H
5.7
30.2
|
L
 -35.7%
H
5.7
30.2
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
174.6
|
1.1
|
L
 -3.4%
H
1.1
1.2
|
L
 -8.1%
H
1.1
1.4
|
L
 -16.9%
H
1.1
1.5
|
L
 -25.7%
H
1.1
1.7
|
L
 -28.5%
H
1.1
2.6
|
L
 -74.7%
H
0.7
4.4
|
L
 -93.6%
H
0.7
19.3
|
L
 -96.2%
H
0.7
31.5
|
| Cingulate Inc |
|
70.2
|
4.8
|
L
 -4.6%
H
4.8
5.1
|
L
 -6.2%
H
4.8
5.5
|
L
 -15.0%
H
4.8
5.9
|
L
 0.4%
H
4.2
6.0
|
L
 26.1%
H
3.2
11.9
|
L
 570.8%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
61.1
|
4.3
|
L
 2.1%
H
4.1
4.5
|
L
 3.6%
H
4.1
4.7
|
L
 -3.2%
H
3.3
4.8
|
L
 -25.1%
H
3.3
6.6
|
L
 -28.9%
H
3.3
13.5
|
L
 -53.6%
H
2.3
13.5
|
L
 -97.0%
H
2.3
159.6
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
17.0
|
1.8
|
L
 -13.5%
H
1.8
2.1
|
L
 -25%
H
1.8
2.4
|
L
 -28.6%
H
1.8
2.6
|
L
 -27.7%
H
1.8
3.1
|
L
 -68.9%
H
1.8
6.5
|
L
 -97.6%
H
1.8
133.5
|
L
 -99.4%
H
1.8
309.2
|
L
 -100.0%
H
1.8
9567
|
| Compass Therapeutics Inc |
|
203.5
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -38.9%
H
1.1
1.9
|
L
 -52.9%
H
1.1
2.6
|
L
 -44.1%
H
1.1
2.6
|
L
 -67.6%
H
1.1
6.9
|
L
 -42.3%
H
0.8
6.9
|
L
 -67.7%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
7.2
|
4.9
|
L
 -4.3%
H
4.9
5.2
|
L
 -3.7%
H
4.9
5.5
|
L
 -17%
H
4.9
6.1
|
L
 18.2%
H
3.9
6.2
|
L
 -40.8%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
73350000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
32.2
|
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 -7.9%
H
0.3
0.4
|
L
 -23.9%
H
0.3
0.5
|
L
 -39.7%
H
0.3
0.7
|
L
 -63.2%
H
0.3
3.6
|
L
 -66.0%
H
0.3
3.6
|
L
H
0.3
10.9
|
L
H
0.3
10.9
|
| Cocrystal Pharma Inc |
|
22.5
|
1.2
|
L
 1.7%
H
1.1
1.2
|
L
 2.6%
H
1.1
1.3
|
L
 5.4%
H
1.1
1.3
|
L
 11.4%
H
0.8
1.3
|
L
 -12.0%
H
0.8
2.0
|
L
 -38.4%
H
0.8
3.3
|
L
 -90.5%
H
0.8
13.0
|
L
 -99.4%
H
0.8
186.5
|
| Collegium pharma Inc |
|
698.4
|
22.5
|
L
 -0.5%
H
22.3
22.9
|
L
 0.7%
H
21.8
23.7
|
L
 -17.6%
H
21.7
28.3
|
L
 -36.7%
H
21.7
38.5
|
L
 -35.9%
H
21.7
50.8
|
L
 1.2%
H
21.0
50.8
|
L
 10.2%
H
14.0
50.8
|
L
 45.5%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
12,550.2
|
116.1
|
L
 -2.0%
H
114.5
120.4
|
L
 1.1%
H
108.4
120.4
|
L
 -5.8%
H
108.3
126.4
|
L
 42.4%
H
80.1
126.4
|
L
 38.5%
H
28.7
126.4
|
L
 266.9%
H
20.8
126.4
|
L
 472.2%
H
15.8
126.4
|
L
 1688.9%
H
6.1
126.4
|
| Cosmos Health Inc |
|
35.2
|
0.4
|
L
 -7.9%
H
0.4
0.4
|
L
 16.7%
H
0.3
0.5
|
L
 66.7%
H
0.2
0.5
|
L
 66.7%
H
0.2
0.5
|
L
 -67.9%
H
0.2
1.3
|
L
 -80.8%
H
0.2
2.1
|
L
 -99.7%
H
0.2
150
|
L
 -99.8%
H
0.2
312.5
|
| Cumberland Pharma Inc |
|
114.0
|
7.6
|
L
 -5.0%
H
7.5
8.1
|
L
 5.8%
H
7.0
8.4
|
L
 -2.9%
H
6.2
9.3
|
L
 25.8%
H
5.4
9.3
|
L
 148.7%
H
1.9
9.3
|
L
 236.7%
H
1.0
9.3
|
L
 176.7%
H
1.0
9.3
|
L
 52.8%
H
1.0
9.3
|
| Corbus Pharma Holdings Inc |
|
138.1
|
7.1
|
L
 -4.2%
H
7.0
7.6
|
L
 -1.7%
H
7.0
8.0
|
L
 -33.2%
H
6.3
11.6
|
L
 -12.7%
H
6.3
11.6
|
L
 -38.0%
H
6.3
20.6
|
L
 5%
H
3.0
61.9
|
L
 -77.1%
H
2.1
61.9
|
L
 -96.2%
H
2.1
323.4
|
| Corvus Pharma Inc |
|
977.5
|
11.6
|
L
 -1.5%
H
11.4
12.0
|
L
 -7.4%
H
11.4
13.5
|
L
 -17.5%
H
11.4
15.1
|
L
 -10.3%
H
11.4
16.5
|
L
 79.3%
H
6.3
27.0
|
L
 659.5%
H
1.1
27.0
|
L
 70.9%
H
0.6
27.0
|
L
 -26.6%
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
588.3
|
2.7
|
L
 -1.8%
H
2.7
2.8
|
L
 -4.3%
H
2.7
3
|
L
 -17.9%
H
2.7
3.9
|
L
 -18.7%
H
2.7
4.0
|
L
 12.0%
H
2.3
8.2
|
L
 110.9%
H
0.4
8.2
|
L
 -48.7%
H
0.4
8.2
|
L
 -82.7%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
6.1
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 4.6%
H
0.9
1
|
L
 5.8%
H
0.7
1.2
|
L
 43.8%
H
0.6
1.2
|
L
 -81.0%
H
0.6
6.7
|
L
 -99.9%
H
0.6
2721.6
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Korsana Biosciences Inc |
|
1,411.8
|
31
|
L
 -16.6%
H
30.6
37.3
|
L
 -8.1%
H
30.6
37.3
|
L
 12.7%
H
19.7
37.3
|
L
 41.0%
H
19.7
37.3
|
L
 36.3%
H
7.2
59.4
|
L
 19.7%
H
7.2
59.4
|
L
 -93.4%
H
7.2
498.4
|
L
H
7.2
3199
|
| Cytokinetics Inc |
|
8,989.3
|
64.7
|
L
 -1.5%
H
64.4
65.9
|
L
 -7.5%
H
64.4
70.2
|
L
 -16.1%
H
64.4
79.9
|
L
 -20.4%
H
64.4
88.3
|
L
 33.9%
H
47.2
88.3
|
L
 108.9%
H
26.0
110
|
L
 95.2%
H
26.0
110
|
L
 638.1%
H
5.8
110
|
| Cellectis (ADR) |
|
148.1
|
1.5
|
L
 2.8%
H
1.4
1.5
|
L
 0.7%
H
1.4
1.6
|
L
 -53.9%
H
1.3
3.6
|
L
 -47.3%
H
1.3
3.6
|
L
 -57.6%
H
1.3
5.5
|
L
 -14.5%
H
1.0
5.5
|
L
 -89.0%
H
1.0
13.7
|
L
 -94.2%
H
1.0
38.9
|
| Connect Biopharma Holdings Ltd (ADR) |
|
60.2
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -16.3%
H
1.1
1.3
|
L
 -53.0%
H
1.1
2.9
|
L
 -49.1%
H
1.1
2.9
|
L
 -37.2%
H
1.1
3.8
|
L
 47.9%
H
0.5
3.8
|
L
 -95.0%
H
0.5
25.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
15.3
|
0.8
|
L
 5.4%
H
0.8
0.8
|
L
 4%
H
0.7
0.9
|
L
 -2.5%
H
0.7
0.9
|
L
 -62.5%
H
0.7
2.2
|
L
 -63.6%
H
0.7
3.8
|
L
 -85.9%
H
0.3
9.2
|
L
 -96.2%
H
0.3
30.1
|
L
 -99.3%
H
0.3
429.6
|
| Journey Medical Corp |
|
173.3
|
6.1
|
L
 -2.9%
H
6.1
6.4
|
L
 -16.6%
H
6.1
7.6
|
L
 -22.4%
H
6.1
8.2
|
L
 -10.4%
H
6
8.2
|
L
 -14.7%
H
4.3
9.6
|
L
 108.1%
H
2.6
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Dermata Therapeutics Inc |
|
5.6
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.3
|
L
 -30.1%
H
1.1
1.7
|
L
 -5.8%
H
1.0
1.7
|
L
 -76.9%
H
1.0
5.9
|
L
 5.6%
H
0.2
7.1
|
L
 -98.6%
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
726.5
|
11.6
|
L
 -0.3%
H
11.4
11.8
|
L
 -7.6%
H
11.3
12.7
|
L
 -18.3%
H
11.3
15.1
|
L
 -25.9%
H
11.3
17.4
|
L
 23.5%
H
8.9
26.2
|
L
 -19.7%
H
0.5
26.2
|
L
 -76.9%
H
0.5
56
|
L
 -96.9%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
38.7
|
4.0
|
L
 -0.5%
H
4.0
4.1
|
L
 -3.1%
H
3.9
4.2
|
L
 -8.9%
H
3.8
5.1
|
L
 -49.6%
H
3.8
8.9
|
L
 62.4%
H
0.7
20.3
|
L
 -32.6%
H
0.7
20.3
|
L
 -93.0%
H
0.7
62.7
|
L
 -99.5%
H
0.7
882
|
| Eledon Pharma Inc |
|
215.3
|
2.7
|
L
 -1.1%
H
2.6
2.7
|
L
H
2.6
3.1
|
L
 -22.3%
H
2.6
3.5
|
L
 -33.1%
H
2.6
4.3
|
L
 9.5%
H
1.4
4.6
|
L
 119.0%
H
1.1
5.4
|
L
 -60.2%
H
1.1
6.8
|
L
 -99.0%
H
1.1
338.6
|
| Enanta Pharma Inc |
|
346.0
|
11.9
|
L
 -1%
H
11.6
12
|
L
 -5.1%
H
11.6
12.6
|
L
 -15.7%
H
11.6
15.1
|
L
 -13.4%
H
11.6
15.5
|
L
 52.1%
H
7.1
17.2
|
L
 -0.1%
H
4.1
17.8
|
L
 -78.8%
H
4.1
102
|
L
 -55.0%
H
4.1
127.8
|
| Entera Bio Ltd |
|
474.4
|
2.7
|
L
 -2.1%
H
2.7
2.9
|
L
 -9.6%
H
2.7
3.1
|
L
 -19.9%
H
2.7
3.6
|
L
 77.9%
H
1.4
4.2
|
L
 52.2%
H
0.9
4.2
|
L
 285.9%
H
0.5
4.2
|
L
 -43.0%
H
0.5
5.2
|
L
H
0.5
10.2
|
| Evolus Inc |
|
526.4
|
8.0
|
L
 1.4%
H
7.7
8
|
L
 -0.5%
H
7.7
8.5
|
L
 -9.2%
H
7.6
9.3
|
L
 14.4%
H
5.4
9.3
|
L
 30.9%
H
3.9
9.3
|
L
 -13.3%
H
3.9
17.8
|
L
 1.3%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
4,984.1
|
14.3
|
L
 -1.9%
H
14.2
14.9
|
L
 -7.1%
H
13.5
15.8
|
L
 -19.0%
H
13.5
20.4
|
L
 -5.3%
H
13.5
21.6
|
L
 646.1%
H
1.8
24.3
|
L
 533.3%
H
1.0
24.3
|
L
 -25.9%
H
1.0
24.3
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
4.0
|
3.4
|
L
 -5.0%
H
3.4
3.9
|
L
 -8.5%
H
3.4
4.0
|
L
 -31.8%
H
3.4
5.5
|
L
 -45.4%
H
3.3
9.9
|
L
 -87.8%
H
3.2
71.5
|
L
 -99.6%
H
3.2
984.4
|
L
 -100.0%
H
3.2
75750
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,648.7
|
57.7
|
L
 -3.0%
H
57.2
60.6
|
L
 1.1%
H
53.6
60.6
|
L
 -10.5%
H
53.6
65.5
|
L
 69.8%
H
33.9
66.4
|
L
 189.4%
H
14.3
66.4
|
L
 1143.1%
H
3.0
66.4
|
L
 1051.3%
H
2.0
66.4
|
L
H
2.0
66.4
|
| Exelixis Inc |
|
14,411.0
|
58.2
|
L
 0.4%
H
57.6
58.6
|
L
 -0.6%
H
56.3
59.2
|
L
 6.6%
H
53.4
59.7
|
L
 10.0%
H
50.0
59.7
|
L
 49.5%
H
33.8
59.7
|
L
 170.8%
H
18.6
59.7
|
L
 185.8%
H
14.9
59.7
|
L
 290.6%
H
10.0
59.7
|
| Hyperion DeFi Inc |
|
62.8
|
4.0
|
L
 -3.1%
H
3.9
4.2
|
L
 16.4%
H
3.6
4.2
|
L
 23.9%
H
3.0
4.2
|
L
 18.8%
H
2.3
4.2
|
L
 -58.0%
H
2.3
11.9
|
L
 -96.8%
H
0.0
205.6
|
L
 -99.0%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
312.1
|
3.6
|
L
 -0.8%
H
3.6
3.7
|
L
 -9.3%
H
3.5
4.2
|
L
 -25.7%
H
3.4
5.3
|
L
 -74.9%
H
3.4
15.9
|
L
 -74.3%
H
3.4
19.1
|
L
 -57.2%
H
3.4
31.0
|
L
 -69.1%
H
2.2
31.0
|
L
 -88.8%
H
2.2
39.4
|
| Fortress Biotech Inc |
|
76.0
|
2.3
|
L
H
2.3
2.3
|
L
 -9.2%
H
2.3
2.6
|
L
 -22.2%
H
2.3
3.0
|
L
 -27.4%
H
2.3
3.8
|
L
 -38.2%
H
2.2
4.5
|
L
 -49.3%
H
1.2
5.3
|
L
 -95.7%
H
1.2
57.2
|
L
 -94.9%
H
1.2
91.5
|
| Kyntra Bio Inc |
|
28.1
|
6.9
|
L
 -0.9%
H
6.9
7.0
|
L
 -2.3%
H
6.7
7.4
|
L
 -13.0%
H
6.7
8.7
|
L
H
6.7
8.7
|
L
 -43.9%
H
6.3
12.6
|
L
 -64.7%
H
4.5
73.3
|
L
 -97.4%
H
4.5
642.3
|
L
 -98.7%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
261.1
|
8.8
|
L
 -4.9%
H
8.7
9.2
|
L
 -19.2%
H
8.7
11.0
|
L
 -46.4%
H
8.7
17.0
|
L
 -21.4%
H
8.7
23.6
|
L
 369.0%
H
1.8
23.6
|
L
 -58.4%
H
1.3
53.8
|
L
 -94.4%
H
1.3
157.5
|
L
H
1.3
572.4
|
| Frequency Therapeutics Inc |
|
-
|
9.6
|
L
H
9.4
9.6
|
L
 -18.9%
H
9.4
11.9
|
L
 -26.8%
H
9.4
15.2
|
L
 -30.5%
H
9.4
15.6
|
L
 -75.2%
H
5.2
55.9
|
L
 -49.8%
H
5.2
55.9
|
L
 -97.5%
H
5.2
394
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
285.4
|
3.7
|
L
 -1.1%
H
3.7
3.8
|
L
 -0.8%
H
3.7
3.9
|
L
 -2.6%
H
3.7
3.9
|
L
 -0.5%
H
3.4
3.9
|
L
 -54.7%
H
2.8
15.7
|
L
 -10.3%
H
2.3
15.7
|
L
 -86.4%
H
2.3
29.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
1,636.4
|
23.8
|
L
 -2.5%
H
23.5
24.6
|
L
 -17.0%
H
23.4
29.2
|
L
 -15.2%
H
23.4
29.2
|
L
 -3.1%
H
23.4
31.4
|
L
 71.4%
H
12.0
31.4
|
L
 134.6%
H
5.1
31.4
|
L
 16.0%
H
5.1
31.4
|
L
H
5.1
31.4
|
| Eocene |
|
3.9
|
3.6
|
L
 0.3%
H
3.6
3.8
|
L
 4.3%
H
3.3
3.8
|
L
 -10.4%
H
3.3
4.9
|
L
 515.3%
H
0.5
5.5
|
L
 152.1%
H
0.4
5.5
|
L
 -52.0%
H
0.2
13.6
|
L
 -99.3%
H
0.2
563.4
|
L
 -99.6%
H
0.2
4870.8
|
| Galecto Inc |
|
1,275.5
|
20.7
|
L
 1.9%
H
19.8
20.8
|
L
 -9.3%
H
19.4
23.4
|
L
 -31.8%
H
19.4
31.6
|
L
 -6.1%
H
19.4
34.9
|
L
 385.0%
H
3.5
38.3
|
L
 3462.1%
H
0.5
38.3
|
L
 436.6%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
902.8
|
14.0
|
L
 -1.8%
H
13.7
14.5
|
L
 -16.6%
H
13.4
17.9
|
L
 -17.6%
H
13.4
22.3
|
L
 -19.4%
H
13.4
22.3
|
L
 7.8%
H
8.7
27.4
|
L
 -90.1%
H
8.7
353
|
L
 -93.9%
H
8.7
416
|
L
 -98.1%
H
8.7
2605
|
| Genelux Corp |
|
112.2
|
2.5
|
L
 2.1%
H
2.4
2.5
|
L
 -2.0%
H
2.4
2.6
|
L
 -8.8%
H
2.3
3.0
|
L
 -13.0%
H
2.3
3.2
|
L
 -43.3%
H
2.3
8.5
|
L
 -90.8%
H
1.6
28.3
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
2.7
|
3.3
|
L
 -6.5%
H
3.3
3.6
|
L
 -4.9%
H
3.3
4.2
|
L
 -18.2%
H
3.3
4.2
|
L
 585.4%
H
0.5
10.0
|
L
 1466.7%
H
0.2
13.0
|
L
 743.6%
H
0.1
13.0
|
L
 17.9%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
66.9
|
10.9
|
L
 0.1%
H
10.2
11.0
|
L
 -8.4%
H
10.0
12.5
|
L
 -21.9%
H
10.0
17.1
|
L
 -19.1%
H
9.1
21.4
|
L
 -95.4%
H
9.1
309.6
|
L
 -82.9%
H
9.1
309.6
|
L
 -98.8%
H
9.1
1215.6
|
L
H
9.1
2172
|
| GT Biopharma Inc |
|
12.4
|
6.9
|
L
 0.9%
H
6.6
7.2
|
L
 -8.0%
H
6.4
7.8
|
L
 -9.9%
H
4.9
12.0
|
L
 -39.6%
H
4.9
12.5
|
L
 -65.6%
H
4.9
34.3
|
L
 -96.3%
H
4.9
266.5
|
L
 -99.9%
H
4.9
5610
|
L
 -100.0%
H
4.9
1003297.5
|
| Genenta Science SpA (ADR) |
|
32.8
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -10.5%
H
0.6
0.8
|
L
 -40.9%
H
0.6
1.2
|
L
 -63.2%
H
0.6
2.0
|
L
 -78.4%
H
0.6
10
|
L
 -88.3%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
2,562.2
|
35.9
|
L
 -0.3%
H
35.5
37.2
|
L
 2.4%
H
34.4
37.7
|
L
 -26.7%
H
34.4
51.0
|
L
 -25.4%
H
34.4
57.1
|
L
 40.2%
H
24.5
94.9
|
L
 5.7%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,002.3
|
7.4
|
L
 2.1%
H
7.3
7.4
|
L
 -0.7%
H
7.2
7.5
|
L
 -8.0%
H
7.2
8.1
|
L
 1.8%
H
7.0
8.4
|
L
 -25.5%
H
7.0
10.2
|
L
 -21.8%
H
5.3
12.2
|
L
 -51.9%
H
5.3
15.9
|
L
 -54.4%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
19.2
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -2.5%
H
0.7
0.8
|
L
 4.1%
H
0.6
0.9
|
L
 -23.8%
H
0.6
1.2
|
L
 -60.5%
H
0.5
2.5
|
L
 -51.0%
H
0.5
3.8
|
L
 -97.5%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
46.7
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
H
1.0
1.0
|
L
 9.1%
H
0.8
1.1
|
L
 152.6%
H
0.3
1.1
|
L
 -53.9%
H
0.3
2.4
|
L
 -56.4%
H
0.3
8.2
|
L
 -94.6%
H
0.3
18.2
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,402.8
|
41.3
|
L
 0.2%
H
40.9
41.6
|
L
 -3.5%
H
39.7
43.3
|
L
 7.2%
H
38.3
43.5
|
L
 19.8%
H
32.3
43.5
|
L
 54.2%
H
25.5
43.5
|
L
 13.7%
H
18.6
43.5
|
L
 9.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,239.7
|
33.1
|
L
 -0.1%
H
32.6
33.3
|
L
 -0.2%
H
31.9
34.9
|
L
 -16.9%
H
31.9
42.5
|
L
 -22.5%
H
31.9
47.5
|
L
 -30.9%
H
28.5
54.9
|
L
 135.2%
H
7.6
59.2
|
L
 248.5%
H
5.4
59.2
|
L
 765.7%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,423.0
|
13.9
|
L
 0.3%
H
13.9
14.1
|
L
 0.9%
H
13.6
14.6
|
L
 14.5%
H
11.8
14.6
|
L
 35.7%
H
10.0
14.6
|
L
 -12.2%
H
9.8
16.4
|
L
 -11.9%
H
9.8
21.9
|
L
 -61.9%
H
7.4
37.5
|
L
 13.5%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,945.0
|
8.4
|
L
 -2.3%
H
8.4
8.8
|
L
 -0.2%
H
8.2
9.5
|
L
 11.4%
H
7.6
9.5
|
L
 8.2%
H
6.7
9.6
|
L
 237.6%
H
2.0
12.4
|
L
 411.5%
H
1.3
12.4
|
L
 -17.7%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
3,540.2
|
36.7
|
L
 -0.1%
H
36.2
37.0
|
L
 -5.0%
H
35.6
40
|
L
 -8.4%
H
35.6
42.7
|
L
 1.1%
H
34.0
42.7
|
L
 42.9%
H
25.4
42.7
|
L
 32.8%
H
13.5
47.7
|
L
 44.6%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
287.4
|
2.1
|
L
 -1.9%
H
2.0
2.2
|
L
 -10.4%
H
2.0
2.3
|
L
 -17.6%
H
2.0
2.6
|
L
 10.2%
H
1.8
2.6
|
L
 19.8%
H
1.3
2.6
|
L
 64.8%
H
0.8
4.2
|
L
 -83.1%
H
0.8
14.0
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
784.8
|
11.0
|
L
 -6.2%
H
10.8
12.0
|
L
 -13.8%
H
10.8
12.9
|
L
 -19.4%
H
10.8
15.1
|
L
 9.3%
H
7.8
15.1
|
L
 435.1%
H
2.0
15.1
|
L
 219.8%
H
1.3
15.1
|
L
H
0.7
15.1
|
L
H
0.7
15.1
|
| Immuneering Corp (Class A) |
|
276.3
|
4.3
|
L
 -1.6%
H
4.3
4.4
|
L
 -4.3%
H
4.2
4.7
|
L
 -17.6%
H
4.2
5.4
|
L
 -7.2%
H
4.0
5.7
|
L
 -53.7%
H
3.9
9.6
|
L
 -44.3%
H
1
10.1
|
L
 -84.5%
H
1
33.3
|
L
H
1
34.0
|
| Immatics N.V |
|
1,274.1
|
8.4
|
L
 0.5%
H
8.3
8.5
|
L
 -5.1%
H
8.1
8.9
|
L
 -3.7%
H
8.1
9.9
|
L
 -16.5%
H
8.1
10.9
|
L
 14.2%
H
6.9
12.4
|
L
 -28.5%
H
3.3
13.8
|
L
 -36.3%
H
3.3
14.9
|
L
H
3.3
18.4
|
| Immunic Inc |
|
127.4
|
9.3
|
L
 0.2%
H
9.1
9.5
|
L
 -9.8%
H
9.1
11.3
|
L
 -43.3%
H
9.1
17.2
|
L
 -36.5%
H
9.1
17.4
|
L
 6.3%
H
5.1
17.4
|
L
 -31.3%
H
5.1
21.1
|
L
 -89.9%
H
5.1
145
|
L
 -99.6%
H
5.1
3900
|
| Incyte |
|
25,112.2
|
123.9
|
L
 -0.4%
H
123.1
126
|
L
 -2.9%
H
123.0
128.7
|
L
 -3.2%
H
120.0
130.8
|
L
 14.2%
H
106.5
132.6
|
L
 47.2%
H
81.1
132.6
|
L
 113.2%
H
50.3
132.6
|
L
 79.6%
H
50.3
132.6
|
L
 39.2%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
513.0
|
3.9
|
L
 -3.8%
H
3.5
4
|
L
 -2.0%
H
2.9
4.2
|
L
 231.9%
H
1.1
4.2
|
L
 8.5%
H
0.9
4.2
|
L
 30.1%
H
0.9
8.6
|
L
 42.1%
H
0.3
13.4
|
L
 -56.3%
H
0.3
13.4
|
L
 -99.2%
H
0.3
8800
|
| Indivior PLC |
|
4,227.9
|
35.8
|
L
 -0.5%
H
35.7
36.2
|
L
 0.4%
H
34.6
36.9
|
L
 -1%
H
33.7
36.9
|
L
 -13.6%
H
33.7
42.8
|
L
 56.8%
H
22.6
42.8
|
L
 60.7%
H
7.3
42.8
|
L
 1094%
H
2.8
42.8
|
L
 740.8%
H
0.4
42.8
|
| InMed Pharma Inc |
|
7.6
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
 -3.5%
H
1.3
1.5
|
L
 -11.0%
H
1.3
2.3
|
L
 -36.7%
H
0.6
2.5
|
L
 -91.0%
H
0.6
41.6
|
L
 -99.8%
H
0.6
1185
|
L
 -99.9%
H
0.6
32175
|
| Inovio Pharma Inc |
|
122.0
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 -2.5%
H
1.2
1.3
|
L
 -5.6%
H
1.1
1.5
|
L
 7.3%
H
0.6
1.5
|
L
 -53.2%
H
0.6
2.7
|
L
 202.6%
H
0.3
14.8
|
L
 -84.8%
H
0.3
14.8
|
L
 -87.6%
H
0.3
33.8
|
| Insmed Inc |
|
25,731.9
|
117.8
|
L
 -3.1%
H
115.9
122.9
|
L
 -5.0%
H
115.9
124.5
|
L
 -5.0%
H
115.9
130.8
|
L
 13.9%
H
96.4
137.7
|
L
 -16.4%
H
90.4
212.8
|
L
 350.2%
H
21.9
212.8
|
L
 336.2%
H
16.0
212.8
|
L
 698.3%
H
10.2
212.8
|
| Innoviva Inc |
|
1,498.4
|
20.7
|
L
 0.4%
H
20.4
20.8
|
L
 -1.5%
H
20.2
21.4
|
L
 -1.4%
H
20.2
21.5
|
L
 -12.3%
H
20.2
24.0
|
L
 9.5%
H
16.5
25.1
|
L
 60.8%
H
12.2
25.1
|
L
 28.2%
H
10.6
25.1
|
L
 81.0%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
7,395.2
|
44.5
|
L
 1.6%
H
43.6
45.3
|
L
 -4.8%
H
43.0
46.8
|
L
 -28.3%
H
43.0
64.2
|
L
 -41.9%
H
43.0
86.7
|
L
 -30.4%
H
43.0
86.7
|
L
 4.2%
H
24.0
86.7
|
L
 22.9%
H
24.0
86.7
|
L
 26.7%
H
24.0
86.7
|
| Ironwood Pharma Inc (Class A) |
|
682.4
|
4.1
|
L
 -1.4%
H
4.1
4.3
|
L
 -2.4%
H
4.1
4.6
|
L
H
3.9
4.6
|
L
 5.6%
H
3.6
4.9
|
L
 201.5%
H
1.3
5.8
|
L
 -55.5%
H
0.5
15.7
|
L
 -69.3%
H
0.5
15.7
|
L
 -68.6%
H
0.5
17.7
|
| I-Mab (ADR) |
|
159.1
|
1.4
|
L
 -4.8%
H
1.3
1.4
|
L
 -15.3%
H
1.3
1.7
|
L
 -27.0%
H
1.3
2.0
|
L
 -13.8%
H
1.3
2.3
|
L
 -61.2%
H
1.3
6.8
|
L
 15%
H
0.6
6.8
|
L
 -98.0%
H
0.6
76.8
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
9.4
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 -1.7%
H
1.2
1.3
|
L
 3.6%
H
1.1
2.0
|
L
 7.4%
H
1.0
2.0
|
L
 -39.6%
H
0.7
2.4
|
L
 -39.9%
H
0.7
6.0
|
L
 -74.5%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
189.9
|
1.7
|
L
H
1.6
1.7
|
L
 -11.0%
H
1.6
1.9
|
L
 -22.7%
H
1.6
2.3
|
L
 -10.5%
H
1.6
2.7
|
L
 -7.6%
H
1.2
2.7
|
L
 -36.3%
H
1.2
3.5
|
L
 -74.6%
H
1.2
7.2
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
4.0
|
7.7
|
L
 9.1%
H
6.8
12.1
|
L
 180%
H
2.5
41.5
|
L
 746.2%
H
0.2
41.5
|
L
 187.3%
H
0.2
41.5
|
L
 -89.8%
H
0.2
85.4
|
L
 -99.9%
H
0.2
27772.5
|
L
 -100.0%
H
0.2
10473750
|
L
 -100.0%
H
0.2
880621875
|
| Jazz Pharma PLC |
|
15,446.4
|
238.0
|
L
 0.7%
H
235.7
239.1
|
L
 -2.4%
H
231.6
244.6
|
L
 -6.5%
H
231.6
266.4
|
L
 3.5%
H
225.0
266.4
|
L
 83.6%
H
125.8
266.4
|
L
 80.6%
H
95.5
266.4
|
L
 75.8%
H
95.5
266.4
|
L
 87.1%
H
86.9
266.4
|
| Kala Pharma Inc |
|
9.3
|
0.5
|
L
 -14.3%
H
0.5
0.6
|
L
 -14.3%
H
0.5
0.6
|
L
 -40%
H
0.5
1.1
|
L
 -84%
H
0.5
3.0
|
L
 -100.0%
H
0.5
988.5
|
L
 -99.9%
H
0.5
1030
|
L
 -100.0%
H
0.5
7645.3
|
L
H
0.5
66943.3
|
| Kiniksa Pharma Ltd (Class A) |
|
5,858.0
|
75.1
|
L
 -0.4%
H
74.5
76
|
L
 -5.4%
H
74.5
79.6
|
L
 -5.4%
H
74.5
81.4
|
L
 27.0%
H
56.6
82.9
|
L
 108.0%
H
35.2
82.9
|
L
 351.2%
H
14.1
82.9
|
L
 546.1%
H
7.4
82.9
|
L
H
5.0
82.9
|
| Kiora Pharma Inc |
|
11.6
|
2.6
|
L
 -1.5%
H
2.6
2.6
|
L
 -1.5%
H
2.6
2.9
|
L
 -4.4%
H
2.5
2.9
|
L
 1.5%
H
2.3
2.9
|
L
H
1.8
3.0
|
L
 361.4%
H
0.4
5.6
|
L
 -96.6%
H
0.4
93.6
|
L
 -99.7%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
36.7
|
1.6
|
L
 -6.4%
H
1.6
1.8
|
L
 -9.5%
H
1.6
1.9
|
L
 -12.9%
H
1.2
2.1
|
L
 -82.2%
H
1.2
10.9
|
L
 -76.5%
H
1.2
11.0
|
L
 -90.6%
H
0.6
29.3
|
L
 -98.3%
H
0.6
221.0
|
L
 -98.8%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
230.4
|
11.6
|
L
 0.6%
H
11.3
11.7
|
L
 2.3%
H
11.0
12.1
|
L
 7.8%
H
10.6
12.1
|
L
 6.4%
H
9.7
12.2
|
L
 -26.2%
H
9.7
22.6
|
L
 -64.6%
H
9.1
73
|
L
 -64.8%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
16.7
|
0.5
|
L
 -2.0%
H
0.5
0.5
|
L
 -2.0%
H
0.5
0.6
|
L
H
0.5
0.6
|
L
 -10.7%
H
0.4
0.6
|
L
 -32.4%
H
0.3
2.1
|
L
 13.6%
H
0.3
9.3
|
L
 -83.1%
H
0.3
9.3
|
L
H
0.3
9.3
|
| Lexaria Bioscience Corp |
|
6.9
|
3.3
|
L
 -2.7%
H
3.2
3.5
|
L
 -0.3%
H
3.1
3.8
|
L
 -68.9%
H
2.8
14.4
|
L
 -60%
H
2.8
14.4
|
L
 -84.6%
H
2.8
23.3
|
L
 -76.6%
H
2.8
102.8
|
L
 -96.8%
H
2.8
107.3
|
L
 -94.3%
H
2.8
1143
|
| Lifecore Biomedical Inc |
|
159.0
|
4.2
|
L
 -2.1%
H
4.1
4.4
|
L
 -5.8%
H
4.1
4.6
|
L
 -7.7%
H
4
4.8
|
L
 -27.6%
H
4
5.9
|
L
 -40.5%
H
3.6
9.0
|
L
 -47.8%
H
3.6
9.0
|
L
 -58.9%
H
1.5
12.0
|
L
 -67.6%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
6,011.0
|
301.5
|
L
 0.8%
H
293.9
305.3
|
L
 5.9%
H
280.5
305.3
|
L
 7.6%
H
270.8
305.3
|
L
 5.8%
H
270.8
326.6
|
L
 78.5%
H
163.5
326.6
|
L
 410.4%
H
49.3
326.6
|
L
 235.7%
H
46.8
326.6
|
L
 303.6%
H
36.9
326.6
|
| Atyr Pharma Inc |
|
29.4
|
0.3
|
L
 -11.8%
H
0.3
0.3
|
L
 -21.1%
H
0.3
0.4
|
L
 -43.4%
H
0.3
0.6
|
L
 -46.4%
H
0.3
0.7
|
L
 -68.4%
H
0.3
1.1
|
L
 -81.4%
H
0.3
7.3
|
L
 -97.1%
H
0.3
10.6
|
L
 -99.4%
H
0.3
90.9
|
| Lipocine Inc |
|
17.3
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 -5.4%
H
2.1
2.3
|
L
 1.9%
H
2.1
2.5
|
L
 -15.0%
H
2.0
2.6
|
L
 -23.9%
H
1.8
12.4
|
L
 -37.1%
H
1.8
12.4
|
L
 -88.8%
H
1.8
32.1
|
L
 -96.8%
H
1.8
100.3
|
| Liquidia Corp |
|
6,125.1
|
68.4
|
L
 -3.6%
H
67.5
71.8
|
L
 0.1%
H
65.7
71.8
|
L
 -2.6%
H
62.9
73.1
|
L
 -9.4%
H
62.9
93.6
|
L
 211.9%
H
21.1
93.6
|
L
 972.6%
H
5.7
93.6
|
L
 2284.3%
H
2.6
93.6
|
L
H
2.3
93.6
|
| Lisata Therapeutics Inc |
|
17.1
|
1.6
|
L
 5.3%
H
1.5
1.6
|
L
 -9.2%
H
1.4
1.8
|
L
 -10.2%
H
1.2
2.6
|
L
 -54.1%
H
1.0
3.9
|
L
 -32.8%
H
1.0
5.1
|
L
 -23.7%
H
1.0
5.1
|
L
 -91.4%
H
1.0
18.6
|
L
 -97.8%
H
1.0
174.8
|
| Lantern Pharma Inc |
|
15.6
|
1.2
|
L
 0.8%
H
1.2
1.3
|
L
 -28.7%
H
1.2
1.8
|
L
 -42.2%
H
1.2
2.3
|
L
 -69.1%
H
1.2
4.3
|
L
 -73.4%
H
1.1
4.7
|
L
 -66.6%
H
1.1
12.0
|
L
 -90.0%
H
1.1
12.2
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
800.9
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -11.8%
H
1.8
2.2
|
L
 -22.4%
H
1.8
2.4
|
L
 -18.9%
H
1.8
2.7
|
L
 35.3%
H
1.1
2.7
|
L
 68.2%
H
0.3
3.7
|
L
 -63.6%
H
0.3
6.3
|
L
 -90.3%
H
0.3
19.5
|
| Legend Biotech Corp (ADR) |
|
3,716.7
|
19.1
|
L
 0.3%
H
18.9
19.7
|
L
 8.7%
H
17.2
19.7
|
L
 -8.7%
H
16.9
22.1
|
L
 -35.0%
H
16.9
30.3
|
L
 -41.9%
H
16.2
37.5
|
L
 -69.7%
H
16.2
70.8
|
L
 -59.5%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
3.9
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 6.1%
H
0.5
0.6
|
L
 -5.5%
H
0.5
0.6
|
L
 -25.7%
H
0.5
0.7
|
L
 -67.9%
H
0.5
1.9
|
L
 -99.5%
H
0.1
120
|
L
 -100.0%
H
0.1
2070
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
12.2
|
0.6
|
L
 5.3%
H
0.5
0.7
|
L
 -23.1%
H
0.5
0.8
|
L
 -1.6%
H
0.5
0.9
|
L
 -79.5%
H
0.2
3.7
|
L
 -94.4%
H
0.2
15.8
|
L
 -99.6%
H
0.2
3318.8
|
L
 -99.9%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
14265
|
| Madrigal Pharma Inc |
|
11,934.7
|
516.6
|
L
 0.7%
H
511.3
524.0
|
L
 -3.3%
H
502.6
537.7
|
L
 0.9%
H
502.6
552.1
|
L
 1.3%
H
447.0
569.4
|
L
 21.0%
H
393.6
615
|
L
 236.9%
H
119.8
615
|
L
 508.5%
H
52.3
615
|
L
 4334.0%
H
11.3
615
|
| MediWound Ltd |
|
178.7
|
13.8
|
L
 0.1%
H
13.7
14.0
|
L
 3.7%
H
13
14.0
|
L
 6.5%
H
12.5
14.1
|
L
 -6.8%
H
12.5
15.4
|
L
 -23.2%
H
12.5
20.0
|
L
 53.4%
H
7.5
24
|
L
 -43.3%
H
7.1
28.1
|
L
 -75.6%
H
7.1
60.1
|
| MEI Pharma Inc |
|
49.0
|
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 38.5%
H
1.0
1.5
|
L
 39.8%
H
1.0
1.5
|
L
 65.5%
H
0.8
1.5
|
L
 -46.7%
H
0.7
3.0
|
L
 -80.9%
H
0.7
9
|
L
 -97.5%
H
0.7
71
|
L
 -95.7%
H
0.7
102.8
|
| Macrogenics Inc |
|
238.2
|
3.7
|
L
 -1.6%
H
3.7
3.9
|
L
 -9.4%
H
3.6
4.2
|
L
 -7.0%
H
3.6
4.5
|
L
 -21.8%
H
3.4
5.1
|
L
 117.4%
H
1.3
5.1
|
L
 -19.7%
H
1.0
21.9
|
L
 -81.1%
H
1.0
22.7
|
L
 -88.1%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
10.1
|
0.5
|
L
 2.2%
H
0.5
0.5
|
L
 6.8%
H
0.4
0.5
|
L
 23.7%
H
0.4
0.5
|
L
 30.6%
H
0.3
1.3
|
L
 -80.7%
H
0.2
2.8
|
L
 -47.8%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Mirum Pharma Inc |
|
5,824.4
|
89.7
|
L
 0.4%
H
88.3
90.8
|
L
 -9.2%
H
87.6
98.8
|
L
 -7.3%
H
87.6
103.3
|
L
 -22.0%
H
87.6
130
|
L
 20.8%
H
63.2
130
|
L
 192.0%
H
23.1
130
|
L
 385.1%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
98.4
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -14.1%
H
0.8
0.9
|
L
 -24.0%
H
0.8
1.3
|
L
 -37.8%
H
0.8
1.4
|
L
 -59.3%
H
0.8
3.1
|
L
 -73.7%
H
0.6
3.5
|
L
 -85.9%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,024.7
|
12.0
|
L
 -0.7%
H
11.8
12.2
|
L
 -2.5%
H
11.8
13.7
|
L
 -21.7%
H
11.8
16.0
|
L
 -39.8%
H
11.8
21.3
|
L
 -77.7%
H
6.0
62.8
|
L
 -76.9%
H
6.0
65.0
|
L
 22.1%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,074.0
|
3.3
|
L
 1.5%
H
3.2
3.4
|
L
 -6.7%
H
3.2
3.6
|
L
 -17.9%
H
3.2
4.4
|
L
 -13.0%
H
3.2
4.6
|
L
 -37.3%
H
2.2
6.5
|
L
 -17.7%
H
2.2
7.6
|
L
 -28.6%
H
2.2
7.6
|
L
 8.8%
H
0.7
7.6
|
| Mind Medicine Inc |
|
4,860.1
|
36.2
|
L
 -1.5%
H
36.1
37
|
L
 -6.5%
H
35.9
40.4
|
L
 -16.4%
H
35.9
45.3
|
L
 -14.2%
H
35.9
49.7
|
L
 268.3%
H
9.5
49.7
|
L
 901.9%
H
2.4
49.7
|
L
 -3.9%
H
2.1
49.7
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
127.0
|
2.6
|
L
 -2.6%
H
2.5
2.7
|
L
 -25.2%
H
2.5
3.6
|
L
 68.6%
H
1.4
3.9
|
L
 94.0%
H
1.3
3.9
|
L
 106.4%
H
1.2
3.9
|
L
 23.4%
H
1.1
3.9
|
L
 -33.8%
H
1.1
4.7
|
L
 -63.7%
H
1.1
14.5
|
| TNF Pharma Inc |
|
7.1
|
0.9
|
L
 -14.7%
H
0.9
1.1
|
L
 14.5%
H
0.7
1.2
|
L
 -63.9%
H
0.4
2.6
|
L
 -77.2%
H
0.4
4.1
|
L
 -83.3%
H
0.4
8.2
|
L
 -99.9%
H
0.4
1875
|
L
 -100.0%
H
0.4
29850
|
L
 -100.0%
H
0.4
29850
|
| NewAmsterdam Pharma Co NV |
|
2,699.1
|
22.6
|
L
 -0.7%
H
22.4
23.0
|
L
 3.0%
H
21.3
23.7
|
L
 -15.9%
H
21.0
28.0
|
L
 -30.8%
H
21.0
37.4
|
L
 -15.6%
H
21.0
42.2
|
L
 140.0%
H
5.6
42.2
|
L
 129.2%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Minerva Neurosciences Inc |
|
162.3
|
3.4
|
L
 -1.5%
H
3.4
3.5
|
L
 -1.7%
H
3.3
3.9
|
L
 -29.3%
H
3.3
5.6
|
L
 -21.5%
H
3.3
5.8
|
L
 55.3%
H
2.1
12.5
|
L
 -55.8%
H
1.2
13.5
|
L
 -79.2%
H
1.2
16.8
|
L
 -97.0%
H
1.2
121.7
|
| Nektar Therapeutics |
|
1,948.2
|
57.1
|
L
 -3.9%
H
57.0
61.0
|
L
 -16.5%
H
56.2
69.8
|
L
 -22.6%
H
56.2
77.8
|
L
 -12%
H
56.2
77.8
|
L
 -5.4%
H
33.4
109
|
L
 517.5%
H
6.2
109
|
L
 -79.4%
H
6.2
290.6
|
L
 -79.7%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
17.0
|
3.0
|
L
 2.1%
H
3.0
3.2
|
L
 -12.7%
H
2.8
3.4
|
L
 -14.7%
H
2.8
3.6
|
L
 -17.8%
H
2.8
4.6
|
L
 -86.2%
H
1.8
24.6
|
L
 -99.0%
H
1.2
406
|
L
 -99.7%
H
1.2
1132
|
L
H
1.2
2940
|
| 9 Meters Biopharma Inc |
|
-
|
8.1
|
L
H
8.0
8.2
|
L
 -9.6%
H
8.0
9.1
|
L
 -17.4%
H
8.0
10.0
|
L
 -12.7%
H
8.0
10.4
|
L
 15.1%
H
6.4
10.4
|
L
 40600%
H
0.0
10.4
|
L
 -69.4%
H
0.0
29.2
|
L
 -97.8%
H
0.0
1010
|
| NeuroSense Therapeutics Ltd |
|
13.2
|
7.0
|
L
 -6.1%
H
6.7
7.2
|
L
 3.4%
H
6.4
7.4
|
L
 -7.3%
H
5.6
10.5
|
L
 -54.3%
H
5
19
|
L
 -72.0%
H
5
26.6
|
L
 -58.4%
H
5
52
|
L
H
5
163.6
|
L
H
5
163.6
|
| NRX Pharma Inc |
|
129.9
|
3
|
L
 -1.0%
H
2.9
3.1
|
L
 -11.5%
H
2.9
3.4
|
L
 -13.0%
H
2.9
3.7
|
L
 -15.7%
H
2.8
4.6
|
L
 0.3%
H
1.6
5.1
|
L
 17.2%
H
1.1
54
|
L
 -96.8%
H
1.1
134.9
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
660.1
|
20.2
|
L
 -6.5%
H
20.2
22.0
|
L
 -5.4%
H
20.2
23.2
|
L
 -15.3%
H
20
25.9
|
L
 -17.4%
H
17.8
29.3
|
L
 239.8%
H
5.6
29.3
|
L
 45.1%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
23.3
|
5.1
|
L
 -3.8%
H
5.0
5.6
|
L
 -10.4%
H
4.6
6.3
|
L
 -13.8%
H
4.6
8.6
|
L
 187.0%
H
1.6
9.9
|
L
 -11.7%
H
1.6
15.7
|
L
 -68.6%
H
1.6
30.8
|
L
 -94.0%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,696.1
|
33.3
|
L
 -0.5%
H
32.3
34.1
|
L
 -7.2%
H
31.6
36.1
|
L
 -16.0%
H
31.6
46.7
|
L
 -3.0%
H
31.6
46.7
|
L
 102.6%
H
14.5
57.1
|
L
 293.3%
H
2.8
57.1
|
L
 181.6%
H
1.8
57.1
|
L
H
1.8
57.1
|
| Ocugen Inc |
|
345.9
|
1.0
|
L
 2%
H
1.0
1.1
|
L
 -1.0%
H
1.0
1.1
|
L
 -25%
H
1.0
1.4
|
L
 -26.6%
H
1.0
1.7
|
L
 -37.8%
H
1.0
2.7
|
L
 155%
H
0.3
2.7
|
L
 -86.5%
H
0.3
17.7
|
L
 -99.5%
H
0.2
213.6
|
| Ocular Therapeutix Inc |
|
2,119.3
|
9.7
|
L
 -1.7%
H
9.6
9.9
|
L
 -4.8%
H
9.6
10.6
|
L
 -10.5%
H
9.6
11.5
|
L
 -2.0%
H
8.2
11.7
|
L
 -23.2%
H
6.2
16.4
|
L
 202.5%
H
2
16.4
|
L
 -8.0%
H
2
16.4
|
L
 35.2%
H
2
24.3
|
| Opus Genetics Inc |
|
396.0
|
4.8
|
L
 -2.3%
H
4.7
4.9
|
L
 -9.9%
H
4.6
5.6
|
L
 18.1%
H
3.5
7.1
|
L
 28.3%
H
2.8
7.1
|
L
 190.2%
H
1.5
7.1
|
L
 23.0%
H
0.7
7.1
|
L
 -10.7%
H
0.7
7.1
|
L
 -95.5%
H
0.7
340.8
|
| Olema Pharma Inc |
|
765.6
|
8.8
|
L
 -3.2%
H
8.6
9.0
|
L
 -11.6%
H
8.6
10.1
|
L
 -16.1%
H
8.6
11.2
|
L
 -21.5%
H
8.6
13.1
|
L
 4.8%
H
6.7
36.3
|
L
 -29.9%
H
2.9
36.3
|
L
 -69.3%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
1,453.6
|
20.1
|
L
 -0.3%
H
19.7
20.6
|
L
 8.8%
H
17.7
21.2
|
L
 3.9%
H
16.5
21.2
|
L
 89.8%
H
7.4
21.2
|
L
 378.1%
H
4.1
21.2
|
L
 583.0%
H
0.9
21.2
|
L
 26.4%
H
0.9
21.2
|
L
 72.5%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,364.1
|
13.2
|
L
 -0.2%
H
12.9
13.5
|
L
 2.2%
H
12.5
14
|
L
 -2.2%
H
11.9
14.3
|
L
 39.6%
H
9.3
14.7
|
L
 25.8%
H
7.2
14.9
|
L
 68.5%
H
3.9
16.7
|
L
 -44.6%
H
2.4
24.4
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
196.8
|
4.7
|
L
 -1.3%
H
4.7
4.9
|
L
 1.3%
H
4.6
4.9
|
L
 -1.9%
H
4.5
5.5
|
L
 10%
H
3.9
5.5
|
L
 97.1%
H
2.1
5.5
|
L
 81.9%
H
1.7
5.5
|
L
 -79.2%
H
1.7
31.5
|
L
 -39.7%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
155.8
|
0.6
|
L
 -3.0%
H
0.6
0.7
|
L
 -5.9%
H
0.6
0.7
|
L
 4.9%
H
0.6
0.7
|
L
 -61.9%
H
0.6
1.9
|
L
 -35.4%
H
0.2
2.5
|
L
 -99.2%
H
0.2
360
|
L
 -99.9%
H
0.2
938
|
L
 -100.0%
H
0.2
14368
|
| Ovid Therapeutics Inc |
|
468.7
|
2.4
|
L
 -4%
H
2.4
2.5
|
L
 -11.1%
H
2.4
2.8
|
L
 -14.9%
H
2.4
3.0
|
L
 -4%
H
2.2
3.0
|
L
 71.4%
H
1.2
3.1
|
L
 -34.1%
H
0.2
4.1
|
L
 -30.4%
H
0.2
4.1
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,398.7
|
34.5
|
L
 1.5%
H
33.5
34.7
|
L
 0.0%
H
33.1
36.0
|
L
 -2.4%
H
33.1
40.7
|
L
 9.9%
H
30.6
40.7
|
L
 -9.9%
H
28.3
60.1
|
L
 160.6%
H
9.4
60.1
|
L
 59.6%
H
9.4
60.1
|
L
 26.6%
H
9.4
60.1
|
| Palisade Bio Inc |
|
252.7
|
1.5
|
L
 -7.6%
H
1.5
1.6
|
L
 -14.7%
H
1.5
1.7
|
L
 -27.9%
H
1.5
2.2
|
L
 -24.5%
H
1.5
2.3
|
L
 113.2%
H
0.7
2.9
|
L
 -82.3%
H
0.4
22.4
|
L
 -99.9%
H
0.4
2265
|
L
 -100.0%
H
0.4
594000
|
| Puma biotech Inc |
|
504.3
|
9.8
|
L
 -0.5%
H
9.7
9.9
|
L
 2.6%
H
9.0
10.0
|
L
 7.1%
H
8.8
10.0
|
L
 22.9%
H
7.4
10.0
|
L
 107.0%
H
4.6
10.0
|
L
 238.1%
H
2.1
10.0
|
L
 43.3%
H
1.6
10.0
|
L
 -85.6%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,001.3
|
25.1
|
L
 -1.7%
H
25
25.7
|
L
 2.6%
H
24.0
25.7
|
L
 1.1%
H
23.7
26.9
|
L
 4.8%
H
22.8
27.7
|
L
 -3.6%
H
18.8
27.7
|
L
 -24.2%
H
11.2
36.0
|
L
 -56.6%
H
11.2
82.2
|
L
 -31.9%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.1
|
1.8
|
L
 -0.5%
H
1.8
1.9
|
L
 -3.2%
H
1.8
2.0
|
L
 -15.2%
H
1.8
2.3
|
L
 -4.7%
H
1.7
3.1
|
L
 -65.0%
H
1.7
14.3
|
L
 -98.7%
H
1.7
450
|
L
 -100.0%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| PDS biotech Corp |
|
58.0
|
0.8
|
L
H
0.8
0.8
|
L
 -4.8%
H
0.8
1
|
L
 263.6%
H
0.2
1.1
|
L
 -8.1%
H
0.2
1.1
|
L
 -24.5%
H
0.2
1.6
|
L
 -84.6%
H
0.2
6.9
|
L
 -95.2%
H
0.2
17.1
|
L
 -99.6%
H
0.2
355.4
|
| Phathom Pharma Inc |
|
590.6
|
7.3
|
L
 3.1%
H
7.1
7.4
|
L
 -5.8%
H
6.9
7.8
|
L
 -15.7%
H
6.9
9.7
|
L
 -31.2%
H
6.9
12.6
|
L
 -37.7%
H
6.9
18.3
|
L
 -31.3%
H
2.2
19.7
|
L
 -77.1%
H
2.2
34.4
|
L
H
2.2
64.5
|
| Praxis Precision Medicines Inc |
|
7,839.4
|
280.8
|
L
 -0.4%
H
278.6
289.0
|
L
 -9.6%
H
275.9
314
|
L
 -23.7%
H
275.9
383.3
|
L
 -9.1%
H
275.9
392.7
|
L
 473.4%
H
47.0
392.7
|
L
 1199.9%
H
13
392.7
|
L
 -6.3%
H
11.9
392.7
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.4
|
1.0
|
L
H
1.0
1.0
|
L
 -3.9%
H
0.9
1.1
|
L
 -3.0%
H
0.9
1.3
|
L
 -30.5%
H
0.9
2.3
|
L
 -34.2%
H
0.6
5.4
|
L
 -95.4%
H
0.2
23.3
|
L
 -99.5%
H
0.2
189
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
232.8
|
1.7
|
L
 -3.5%
H
1.6
1.7
|
L
 -12.7%
H
1.6
1.9
|
L
 -32.1%
H
1.6
2.4
|
L
 -8.8%
H
1.4
2.5
|
L
 -21.4%
H
1.3
3.1
|
L
 12.2%
H
1.1
4.6
|
L
 -78.8%
H
0.5
9.1
|
L
 -78.3%
H
0.5
24
|
| Cerenome Inc |
|
15.1
|
2.0
|
L
 6.4%
H
1.9
2.1
|
L
 -2.0%
H
1.9
2.1
|
L
 -32.8%
H
1.9
3.3
|
L
 -49.8%
H
1.9
4.5
|
L
 -80.3%
H
1.9
23.4
|
L
 -93.6%
H
1.9
69.5
|
L
 -99.7%
H
1.9
810
|
L
 -100.0%
H
1.9
401250
|
| PTC Therapeutics Inc |
|
5,230.5
|
62.7
|
L
 0.6%
H
61.7
63.4
|
L
 -7.8%
H
61.2
68
|
L
 -11.8%
H
61.2
73.5
|
L
 -25.8%
H
61.2
90.9
|
L
 5.3%
H
57.7
90.9
|
L
 162.0%
H
17.5
90.9
|
L
 59.5%
H
17.5
90.9
|
L
 437.5%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
9,179.5
|
141.9
|
L
 3.3%
H
138.2
143.5
|
L
 -1.3%
H
134.1
147.7
|
L
 -8.3%
H
134.1
158.0
|
L
 16.1%
H
118.3
160.8
|
L
 115.1%
H
62.2
160.8
|
L
 729.1%
H
13.7
160.8
|
L
 654.2%
H
6.9
160.8
|
L
 734.5%
H
4.5
160.8
|
| Pulmatrix Inc |
|
5.9
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 12.6%
H
1.4
1.8
|
L
 3.9%
H
1.4
1.8
|
L
 5.2%
H
1.4
1.9
|
L
 -64.7%
H
1.2
5.5
|
L
 -25.8%
H
1.2
10.4
|
L
 -89.8%
H
1.2
20.8
|
L
 -99.5%
H
1.2
1396
|
| Polypid Ltd |
|
106.0
|
5.2
|
L
 -2.6%
H
5.2
5.5
|
L
 3.8%
H
5.1
5.5
|
L
 4.8%
H
5.0
5.6
|
L
 9.7%
H
3.7
5.7
|
L
 51.3%
H
3.1
5.7
|
L
 -11.4%
H
2.3
9.2
|
L
 -97.8%
H
2.3
257.1
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
238.5
|
2.9
|
L
 -2.1%
H
2.8
2.9
|
L
 -16.1%
H
2.8
3.4
|
L
 -3.4%
H
2.8
4.2
|
L
 31.8%
H
1.9
4.2
|
L
 31.8%
H
1.0
5.6
|
L
 78.8%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
740.3
|
10.5
|
L
 0.2%
H
10.3
11.2
|
L
 -3.0%
H
10.3
11.5
|
L
 -8.7%
H
10.3
12.3
|
L
 -19.4%
H
9.6
14.8
|
L
 -28.9%
H
9.6
21.3
|
L
 -18.9%
H
6.7
21.3
|
L
 5.7%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
2.5
|
1.5
|
L
 2.0%
H
1.4
1.5
|
L
 -2.0%
H
1.3
1.6
|
L
 -3.2%
H
1.3
2.6
|
L
 -13.7%
H
1.2
2.6
|
L
 -74.1%
H
1.2
14.1
|
L
 -100.0%
H
1.2
7200
|
L
 -100.0%
H
1.2
19360
|
L
 -100.0%
H
1.2
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
96.1
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -7.7%
H
0.2
0.3
|
L
 -4%
H
0.2
0.3
|
L
 -29.4%
H
0.2
0.5
|
L
 -97.8%
H
0.2
10.8
|
L
 -94.2%
H
0.2
17.2
|
L
 -98.8%
H
0.2
20.5
|
L
H
0.2
110
|
| Quoin Pharma Ltd (ADR) |
|
12.9
|
6.4
|
L
 0.8%
H
6.3
6.7
|
L
 -8.3%
H
6.1
7.2
|
L
 18.6%
H
4.7
8.3
|
L
 67.9%
H
3.5
8.3
|
L
 -8.4%
H
3.3
41.8
|
L
 -99.8%
H
3.3
4326
|
L
 -100.0%
H
3.3
3003840
|
L
 -100.0%
H
3.3
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
1,429.5
|
14.5
|
L
 -1.8%
H
14.2
14.9
|
L
H
14.1
16.1
|
L
 -43.6%
H
12.7
26.9
|
L
 -50.2%
H
12.7
36.6
|
L
 -49.6%
H
12.7
39.9
|
L
 -60.2%
H
12.7
60.4
|
L
 -84.8%
H
12.7
95.4
|
L
 -80.0%
H
12.7
179.7
|
| Regeneron Pharma |
|
81,132.7
|
788.0
|
L
 -1%
H
784.1
803.9
|
L
 -0.2%
H
779.7
813.5
|
L
 -4.9%
H
769.6
859.3
|
L
 26.4%
H
619.7
859.3
|
L
 36.6%
H
541
859.3
|
L
 -4.5%
H
476.5
1211.2
|
L
 23.3%
H
476.5
1211.2
|
L
 92.0%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
3,051.0
|
6.2
|
L
H
6.1
6.3
|
L
 3.5%
H
5.7
6.4
|
L
 16.6%
H
5.2
7.7
|
L
 -27.9%
H
4.5
8.8
|
L
 -57.7%
H
4.5
69
|
L
 1523.7%
H
0.1
83.6
|
L
 1241.3%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
10,704.7
|
189.7
|
L
 -0.5%
H
186.9
191.5
|
L
 6.5%
H
176.2
192.5
|
L
 4.4%
H
161.1
192.5
|
L
 37.1%
H
129
192.5
|
L
 52.3%
H
101.0
192.5
|
L
 18.1%
H
101.0
211.1
|
L
 -41.3%
H
101.0
322.3
|
L
 490.7%
H
26.2
327.3
|
| Regenxbio Inc |
|
488.5
|
7.4
|
L
 2.2%
H
7.2
7.7
|
L
 -10.0%
H
7.1
8.3
|
L
 -8.2%
H
7.1
10.1
|
L
 -25.8%
H
7.1
15.9
|
L
 -22.4%
H
5.5
16.2
|
L
 -56.8%
H
5.0
28.8
|
L
 -82.5%
H
5.0
44.4
|
L
 -49.3%
H
5.0
85.1
|
| Rigel Pharma |
|
900.0
|
48.2
|
L
 0.6%
H
47.2
48.5
|
L
 5.1%
H
45.2
49.0
|
L
 6.8%
H
43.8
49.9
|
L
 31.8%
H
35.0
49.9
|
L
 59.1%
H
25.0
52.2
|
L
 4320.2%
H
0.7
52.2
|
L
 1188.2%
H
0.6
52.2
|
L
 1300.6%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
408.5
|
3.8
|
L
 0.5%
H
3.7
3.9
|
L
 -8.8%
H
3.7
4.3
|
L
 -16.4%
H
3.7
4.7
|
L
 -41.2%
H
3.7
7.1
|
L
 132.1%
H
1.5
8
|
L
 37.3%
H
0.2
8
|
L
 -86.8%
H
0.2
38.7
|
L
 -32.6%
H
0.2
54
|
| RenovoRx Inc |
|
74.9
|
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -4.1%
H
1.5
1.8
|
L
 32.8%
H
1.3
2.6
|
L
 74.7%
H
0.8
2.6
|
L
 38.3%
H
0.7
2.6
|
L
 24.8%
H
0.6
2.6
|
L
 -76.4%
H
0.6
12.5
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
25,859.2
|
35.8
|
L
 -0.9%
H
35.5
36.2
|
L
 -10.5%
H
35.5
40.7
|
L
 -1.5%
H
33.4
42.5
|
L
 5.3%
H
32.5
42.5
|
L
 143.5%
H
14.6
42.5
|
L
 246.6%
H
8.2
42.5
|
L
 256.2%
H
2.5
42.5
|
L
H
2.5
42.5
|
| Royalty Pharma PLC (Class A) |
|
25,919.6
|
58.2
|
L
 -0.1%
H
57.7
58.5
|
L
 -1.2%
H
57.6
59.1
|
L
 -5.1%
H
57.6
64.4
|
L
 7.2%
H
53.6
64.4
|
L
 62.7%
H
34.6
64.4
|
L
 121.1%
H
24.1
64.4
|
L
 56.9%
H
24.1
64.4
|
L
H
24.1
64.4
|
| Rhythm Pharma Inc |
|
6,792.9
|
98.7
|
L
 0.4%
H
96.4
99.4
|
L
 -0.4%
H
95.4
101.9
|
L
 -11.5%
H
95.4
114.8
|
L
 -8.3%
H
95.4
119.8
|
L
 1.8%
H
74.5
122.2
|
L
 323.3%
H
21.0
122.2
|
L
 659.5%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
375.5
|
3.9
|
L
 -1.0%
H
3.9
4.1
|
L
 -1.3%
H
3.7
4.1
|
L
 -22.2%
H
3.7
5.2
|
L
 -22.5%
H
3.7
5.6
|
L
 -55.7%
H
1.1
11.5
|
L
 174.6%
H
0.7
11.5
|
L
 -51.6%
H
0.7
11.5
|
L
 -93.4%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
3.0
|
0.5
|
L
 -3.9%
H
0.5
0.5
|
L
 -15.3%
H
0.5
0.6
|
L
 -16.7%
H
0.5
1.6
|
L
 -45.1%
H
0.5
1.6
|
L
 -70.1%
H
0.5
2.8
|
L
 -97.2%
H
0.5
82
|
L
 -100.0%
H
0.5
6500
|
L
 -100.0%
H
0.5
15130
|
| Sunshine Biopharma Inc |
|
3.3
|
0.8
|
L
 5%
H
0.8
0.9
|
L
H
0.8
1.0
|
L
 -27.6%
H
0.8
1.3
|
L
 -58.8%
H
0.8
2.3
|
L
 -94.6%
H
0.8
24.3
|
L
 -100.0%
H
0.8
7397.9
|
L
 -100.0%
H
0.8
596000
|
L
 -100.0%
H
0.8
45037037.0
|
| Scynexis Inc |
|
43.7
|
4.4
|
L
 -1.4%
H
4.4
4.6
|
L
 -1.4%
H
4.3
5
|
L
 -16.5%
H
4.1
6.1
|
L
 13.4%
H
3.5
6.1
|
L
 -49.7%
H
3.5
9.1
|
L
 -83.4%
H
3.5
24.6
|
L
 -90.2%
H
3.5
64.8
|
L
 -98.6%
H
3.5
440.8
|
| Shuttle Pharma Holdings Inc |
|
2.3
|
4.0
|
L
 0.3%
H
3.9
4.2
|
L
 18.6%
H
3.2
4.2
|
L
 13.9%
H
3.1
4.2
|
L
 8.7%
H
2.6
6.2
|
L
 -9.3%
H
0.4
6.2
|
L
 -96.7%
H
0.4
136
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
247.9
|
3.5
|
L
 6.2%
H
3.2
3.5
|
L
 13.1%
H
3
3.5
|
L
 17.4%
H
2.9
3.5
|
L
 -20.1%
H
2.8
4.4
|
L
 -61.3%
H
2.8
9.3
|
L
 -26.8%
H
2.8
12.8
|
L
 -50.1%
H
2.8
27.0
|
L
 19.8%
H
1.9
27.0
|
| SILO Pharma Inc |
|
3.1
|
1.8
|
L
H
1.7
1.8
|
L
 1.7%
H
1.7
1.9
|
L
 -32.2%
H
1.6
2.8
|
L
 -71.9%
H
1.6
8.0
|
L
 118.8%
H
0.2
8.0
|
L
 -2.2%
H
0.2
8.0
|
L
 -81.1%
H
0.2
496
|
L
 -96.5%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
218.9
|
66.9
|
L
 10.1%
H
61.1
67.3
|
L
 3.6%
H
58.3
67.3
|
L
 -13.6%
H
58.3
82.2
|
L
 -8.9%
H
58.3
93.7
|
L
 140.5%
H
27
98.0
|
L
 3209.4%
H
0.3
98.0
|
L
 618.0%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
2,344.6
|
11.6
|
L
 -3.1%
H
11.5
12.2
|
L
 0.7%
H
11.1
12.2
|
L
 -18.9%
H
10.8
15.6
|
L
 26.6%
H
9.0
15.9
|
L
 612.3%
H
1.4
15.9
|
L
 668.9%
H
0.5
15.9
|
L
 15.9%
H
0.5
15.9
|
L
 -99.9%
H
0.5
11100
|
| Soligenix Inc |
|
8.3
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -5%
H
0.4
0.4
|
L
 -2.6%
H
0.3
0.4
|
L
 -79.2%
H
0.3
2.0
|
L
 -95.5%
H
0.3
85.3
|
L
 -99.8%
H
0.3
288.0
|
L
 -100.0%
H
0.3
2015.7
|
| Sonoma Pharma Inc |
|
6.1
|
1.3
|
L
 2.4%
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -5.2%
H
1.2
1.4
|
L
 10.4%
H
1.1
1.5
|
L
 -68.9%
H
0.9
4.6
|
L
 62.8%
H
0.1
6.9
|
L
 -76.3%
H
0.1
8.8
|
L
 -96.6%
H
0.1
74.2
|
| SciSparc Ltd |
|
3.0
|
5.2
|
L
 -3.3%
H
5.2
5.3
|
L
 17.1%
H
4.4
5.6
|
L
 -21.8%
H
4.4
7.2
|
L
 -11.1%
H
4.2
11.5
|
L
 -84.9%
H
3.0
80.1
|
L
 -99.3%
H
3.0
2687.6
|
L
 -100.0%
H
3.0
40049.1
|
L
H
3.0
41769
|
| ARS Pharma Inc |
|
405.7
|
4.1
|
L
 -1.7%
H
4.0
4.2
|
L
 -1.7%
H
4.0
4.6
|
L
 -23.7%
H
4.0
6.1
|
L
 -61.3%
H
4.0
9.0
|
L
 -57.6%
H
4.0
13.2
|
L
 3.0%
H
3.4
18.9
|
L
 -61.5%
H
2.6
18.9
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
17.0
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 -29.2%
H
0.3
0.5
|
L
 -48.5%
H
0.3
0.8
|
L
 -56.4%
H
0.3
1.2
|
L
 -91.9%
H
0.3
4.6
|
L
 -97.8%
H
0.3
19.9
|
L
 -91.5%
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,972.1
|
18.7
|
L
 1.5%
H
18.0
18.8
|
L
 -9.7%
H
18.0
21.2
|
L
 3.0%
H
18.0
23.6
|
L
 11.8%
H
14.8
23.6
|
L
 2.3%
H
14.7
25.3
|
L
 -84.4%
H
10.4
173.3
|
L
 -79.4%
H
10.4
173.3
|
L
 -67.7%
H
10.4
181.8
|
| Sutro Biopharma Inc |
|
265.0
|
16.0
|
L
 1.7%
H
15.0
16.2
|
L
 3.2%
H
14.8
16.6
|
L
 -22.0%
H
14.8
21.8
|
L
 -46.8%
H
14.8
34.1
|
L
 82.2%
H
7.2
43.9
|
L
 -51.6%
H
5.2
61.3
|
L
 -91.7%
H
5.2
237
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,483.8
|
42.7
|
L
 -1.5%
H
42.7
43.7
|
L
 -0.6%
H
41.6
44.5
|
L
 -5.4%
H
40.5
45.9
|
L
 -5.5%
H
40.5
52.5
|
L
 -9.4%
H
40.5
59.7
|
L
 51.4%
H
22
59.7
|
L
 53.4%
H
22
59.7
|
L
 63.0%
H
13.1
61.3
|
| Savara Inc |
|
1,027.3
|
5
|
L
 -1.4%
H
4.9
5.2
|
L
 -7.8%
H
4.9
5.5
|
L
 -10.1%
H
4.9
5.7
|
L
 -14.2%
H
4.9
6.5
|
L
 42.5%
H
3.3
7
|
L
 32.3%
H
1.9
7
|
L
 284.6%
H
1.0
7
|
L
 -43.9%
H
0.7
17.2
|
| China SXT Pharma Inc |
|
3.4
|
2.6
|
L
 0.8%
H
2.5
2.6
|
L
 5.3%
H
2.3
2.7
|
L
 -32.4%
H
1.8
3.8
|
L
 -98.7%
H
1.8
234.2
|
L
 -100.0%
H
1.8
83760
|
L
 -100.0%
H
1.8
613440
|
L
 -100.0%
H
1.8
5472000
|
L
H
1.8
224449238.7
|
| Sanofi (ADR) |
|
98,505.2
|
41.1
|
L
 0.4%
H
40.7
41.1
|
L
 -4.7%
H
40.7
42.8
|
L
 -10.0%
H
40.7
46.1
|
L
 -0.5%
H
40.7
46.1
|
L
 -11.4%
H
40.7
52.7
|
L
 -23.9%
H
40.7
60.1
|
L
 -14.2%
H
36.9
60.1
|
L
 7.2%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
193.8
|
3.3
|
L
 -2.1%
H
3.2
3.4
|
L
 -11.4%
H
3.2
3.9
|
L
 -15.3%
H
3.2
4.1
|
L
 -18.6%
H
3.2
4.5
|
L
 -19.6%
H
3.2
7.8
|
L
 90.7%
H
1.0
10.5
|
L
 -54.7%
H
1.0
10.5
|
L
 -99.2%
H
1.0
458
|
| Tarsus Pharma Inc |
|
3,541.7
|
75.7
|
L
 -0.4%
H
73.9
76.2
|
L
 -4.2%
H
73.9
79.1
|
L
 4.0%
H
69.5
91.5
|
L
 12.8%
H
53.9
91.5
|
L
 37.0%
H
53.9
91.5
|
L
 346.5%
H
12.7
91.5
|
L
 232.3%
H
10.8
91.5
|
L
H
10.8
91.5
|
| Tenax Therapeutics Inc |
|
67.7
|
1.8
|
L
 -4.2%
H
1.8
1.9
|
L
 -2.7%
H
1.8
2.0
|
L
 -2.2%
H
1.7
2.4
|
L
 -86%
H
1.3
19.4
|
L
 -72.2%
H
1.3
19.4
|
L
 -92.1%
H
1.3
61.2
|
L
 -99.9%
H
1.3
3135.0
|
L
 -100.0%
H
1.3
84800
|
| TG Therapeutics Inc |
|
8,790.8
|
57.4
|
L
 -0.2%
H
56.6
58.7
|
L
 1.7%
H
54.8
58.9
|
L
 2.5%
H
52.1
58.9
|
L
 7.2%
H
45.4
59.3
|
L
 62.2%
H
26.8
59.3
|
L
 528.3%
H
6.5
59.3
|
L
 78.6%
H
3.5
59.3
|
L
 649.7%
H
3.3
59.3
|
| Alpha Teknova Inc |
|
500.9
|
9.3
|
L
 0.4%
H
9.1
9.5
|
L
 25.2%
H
7.2
9.5
|
L
 27.1%
H
6.3
9.5
|
L
 79.4%
H
4.7
9.5
|
L
 64.6%
H
1.9
9.5
|
L
 366.5%
H
1.2
10.4
|
L
 -59.4%
H
1.2
28
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
128.5
|
1.0
|
L
 -2.9%
H
1
1.1
|
L
 4.1%
H
0.9
1.1
|
L
 -12.2%
H
0.8
1.2
|
L
 -9.8%
H
0.8
1.5
|
L
 -48.7%
H
0.8
2.4
|
L
 53.0%
H
0.4
2.6
|
L
 -33.1%
H
0.4
2.6
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
169.1
|
9.9
|
L
 1.7%
H
9.6
9.9
|
L
 -13.7%
H
9.6
11.5
|
L
 -20.8%
H
9.6
14.5
|
L
 -18.5%
H
9.4
14.5
|
L
 -60.1%
H
9.4
25.5
|
L
 -99.6%
H
0.2
2656
|
L
 -100.0%
H
0.2
406400
|
L
 -100.0%
H
0.2
601600000
|
| Tenaya Therapeutics Inc |
|
136.8
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -9.0%
H
0.6
0.7
|
L
 -10.3%
H
0.6
0.7
|
L
 -16.4%
H
0.6
1.0
|
L
 -60.9%
H
0.5
2.4
|
L
 -78.4%
H
0.4
7.0
|
L
 -96.8%
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
13.7
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -7.8%
H
0.8
1.1
|
L
 -24.6%
H
0.7
1.5
|
L
 -28.5%
H
0.7
1.5
|
L
 -91.0%
H
0.7
12.2
|
L
 112.8%
H
0.2
12.2
|
L
 -94.3%
H
0.2
15.5
|
L
 -100.0%
H
0.2
1903.5
|
| Travere Therapeutics Inc |
|
5,602.9
|
59.4
|
L
 -2.0%
H
59.1
60.9
|
L
 -8.2%
H
58.3
64.9
|
L
 -8.9%
H
58.3
68.7
|
L
 3.0%
H
53
68.7
|
L
 143.5%
H
22.1
68.7
|
L
 657.2%
H
5.1
68.7
|
L
 141.3%
H
5.1
68.7
|
L
 163.4%
H
5.1
68.7
|
| TherapeuticsMD Inc |
|
23.7
|
2.1
|
L
 -3.8%
H
2.0
2.1
|
L
 -6.0%
H
2.0
2.2
|
L
 -1.0%
H
2.0
2.3
|
L
 2.0%
H
1.9
2.4
|
L
 89.8%
H
1.0
3.0
|
L
 -31.9%
H
0.7
3.1
|
L
 -94.3%
H
0.7
40.9
|
L
 -99.4%
H
0.7
414.8
|
| Universe Pharma INC |
|
23.9
|
4.8
|
L
 1.5%
H
4.6
4.9
|
L
H
4.5
5.0
|
L
 -11.4%
H
3.8
5.9
|
L
 61.0%
H
2.6
18.0
|
L
 14.2%
H
2
18.0
|
L
 -72.0%
H
0.1
64.8
|
L
 -86.5%
H
0.1
64.8
|
L
H
0.1
179.9
|
| Vericel Corp |
|
2,033.4
|
39.7
|
L
 1.0%
H
38.7
39.8
|
L
 -0.8%
H
38.2
40.4
|
L
 -6.1%
H
37.4
43.3
|
L
 -4.8%
H
37.4
49.3
|
L
 31.3%
H
29.0
49.3
|
L
 16.8%
H
29.0
63
|
L
 -19.3%
H
17.3
63
|
L
 1259.9%
H
2
68.9
|
| Veru Inc |
|
43.3
|
2.5
|
L
 1.2%
H
2.5
2.6
|
L
 6.3%
H
2.4
2.6
|
L
 -1.9%
H
2.3
2.9
|
L
 -14.5%
H
2.2
3.4
|
L
 -26.4%
H
2.1
7.3
|
L
 -70.7%
H
2.1
19.2
|
L
 -97.2%
H
2.1
245.5
|
L
 -79.5%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
46.2
|
1.4
|
L
 -4.9%
H
1.3
1.5
|
L
 -20.9%
H
1.3
1.8
|
L
 -46.9%
H
1.3
2.8
|
L
 -9.9%
H
1.3
2.8
|
L
 -73.6%
H
1.3
9.5
|
L
 44.7%
H
0.1
29.3
|
L
 -73.8%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,148.2
|
35.6
|
L
 -3.2%
H
35.1
39.0
|
L
 21.1%
H
28.4
43.1
|
L
 7.0%
H
28.4
43.1
|
L
 -6.1%
H
28.4
43.1
|
L
 33.5%
H
24.9
43.2
|
L
 176.1%
H
8.3
99.4
|
L
 448.8%
H
2.0
99.4
|
L
 2656.6%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
305.3
|
5.1
|
L
 1.4%
H
4.9
5.1
|
L
 -1.2%
H
4.9
5.3
|
L
 -5.3%
H
4.9
5.6
|
L
 -14.4%
H
4.5
6.6
|
L
 3.1%
H
4.3
9.9
|
L
 12.0%
H
3.3
9.9
|
L
 -70.7%
H
3.3
21.4
|
L
 -70.0%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
75.1
|
4.4
|
L
 0.2%
H
4.4
4.5
|
L
 -6.0%
H
4.4
4.9
|
L
 -10.3%
H
4.4
5.9
|
L
 -25.3%
H
4.4
7
|
L
 4.8%
H
3.3
9.8
|
L
 15.3%
H
0.4
11.4
|
L
 -62.0%
H
0.4
13.6
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,319.1
|
20.5
|
L
 -0.9%
H
20.2
21
|
L
 -6.7%
H
20.2
22.4
|
L
 -14.8%
H
20.2
24.8
|
L
 18.2%
H
17.3
24.9
|
L
 5.0%
H
13.2
34.3
|
L
 31.7%
H
9.9
34.3
|
L
 28.3%
H
9.5
39
|
L
 -82.5%
H
4.7
270
|
| Vertex Pharma |
|
133,368.6
|
526.2
|
L
 0.7%
H
518.9
527.7
|
L
 1.9%
H
501.0
529.0
|
L
 -3.9%
H
501.0
560.3
|
L
 10.7%
H
465
560.3
|
L
 39.7%
H
377.0
560.3
|
L
 50.5%
H
341.9
560.3
|
L
 186.6%
H
176.4
560.3
|
L
 480.6%
H
71.5
560.3
|
| Viatris |
|
20,479.4
|
17.8
|
L
 2.4%
H
17.4
18.0
|
L
 4.1%
H
16.9
18.0
|
L
 7.8%
H
16.1
18.0
|
L
 11.9%
H
15.8
18.4
|
L
 83.6%
H
9.4
18.4
|
L
 85.0%
H
6.9
18.4
|
L
 33.3%
H
6.9
18.4
|
L
 -57.6%
H
6.9
47.8
|
| vTv Therapeutics Inc (Class A) |
|
119.4
|
30.2
|
L
 -1.7%
H
29.8
30.9
|
L
 -3.8%
H
29.8
32.4
|
L
 -10.9%
H
29.8
34.8
|
L
 -15.5%
H
28.8
38.8
|
L
 36.2%
H
19.5
44
|
L
 6765.9%
H
0.4
44
|
L
 1550.8%
H
0.4
44
|
L
 321.3%
H
0.4
44
|
| Yarrow Bioscience Inc |
|
215.5
|
25.5
|
L
 -2.0%
H
25.0
27.1
|
L
 -16.5%
H
25.0
32.0
|
L
 -35.3%
H
24
43.3
|
L
 -21.5%
H
23.4
47.0
|
L
 58.1%
H
15.8
47.0
|
L
 -85.1%
H
14.1
224.1
|
L
 -98.1%
H
14.1
1575
|
L
H
14.1
143496
|
| Xenetic Biosciences Inc |
|
5.6
|
2.4
|
L
 -3.2%
H
2.3
2.5
|
L
 -2.9%
H
2.3
3.1
|
L
 -37.3%
H
1.9
4.9
|
L
 -17.6%
H
1.9
4.9
|
L
 -26.5%
H
1.9
13.9
|
L
 -57.9%
H
1.9
13.9
|
L
 -89.2%
H
1.9
23.7
|
L
 -99.4%
H
1.9
1074
|
| Xenon Pharma Inc |
|
3,577.3
|
36.9
|
L
 -2.9%
H
36.5
38.3
|
L
 -35.6%
H
36.1
44.9
|
L
 -39%
H
36.1
64.8
|
L
 -33.5%
H
36.1
72.7
|
L
 1.0%
H
36.0
72.7
|
L
 5.0%
H
26.7
72.7
|
L
 145.1%
H
14.7
72.7
|
L
 371.8%
H
2.1
72.7
|
| Xilio Therapeutics Inc |
|
59.5
|
9.0
|
L
 0.4%
H
8.9
9.2
|
L
H
8.9
9.7
|
L
 -1.6%
H
8.6
9.7
|
L
 0.3%
H
8.3
9.9
|
L
 -15.7%
H
6.5
12.7
|
L
 -70.9%
H
6.5
40.5
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XORTX Therapeutics Inc |
|
3.1
|
1.7
|
L
 -1.7%
H
1.7
1.8
|
L
 1.8%
H
1.7
2.7
|
L
 -15.5%
H
1.6
2.7
|
L
 -19.9%
H
1.6
2.7
|
L
 -92.2%
H
1.6
35.3
|
L
 -98.9%
H
1.6
188.1
|
L
 -99.8%
H
1.6
1377
|
L
H
1.6
1841.6
|
| Zevra Therapeutics Inc |
|
655.6
|
11.0
|
L
 -2.0%
H
11.0
11.3
|
L
 -6.8%
H
11.0
11.9
|
L
 -5.2%
H
11.0
12.9
|
L
 -15.6%
H
9.1
15.0
|
L
 23.4%
H
8.0
15.0
|
L
 127.2%
H
3.9
15.0
|
L
 21.3%
H
3.9
15.0
|
L
 -84.9%
H
1.9
134.4
|
| Zymeworks BC Inc |
|
1,896.4
|
26.5
|
L
 -1.1%
H
26.2
26.9
|
L
 -3.5%
H
26.1
27.9
|
L
 -7.8%
H
25.6
31.3
|
L
 9.1%
H
21.5
31.3
|
L
 62.7%
H
15.8
31.3
|
L
 314.4%
H
6.0
31.3
|
L
 -7.0%
H
4.1
31.3
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
574.3
|
9.2
|
L
 1.4%
H
8.9
9.3
|
L
 -17.3%
H
8.7
11.4
|
L
 -9.5%
H
8.7
11.5
|
L
 33.3%
H
6.5
11.5
|
L
 26.9%
H
4.5
11.5
|
L
 21.3%
H
1.7
20.7
|
L
 21.3%
H
1.7
20.7
|
L
 21.3%
H
1.7
20.7
|
| Neumora Therapeutics Inc |
|
127.8
|
0.7
|
L
 -2.9%
H
0.6
0.7
|
L
 -9.3%
H
0.6
0.8
|
L
 -55.3%
H
0.6
1.6
|
L
 -53.4%
H
0.6
1.8
|
L
 -62.8%
H
0.6
3.7
|
L
 -93.8%
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Conduit Pharma Inc |
|
1.1
|
0.1
|
L
 -33.3%
H
0.1
0.1
|
L
 -57.9%
H
0.1
0.2
|
L
 -96.8%
H
0.1
2.5
|
L
 -99.3%
H
0.1
10.0
|
L
 -100.0%
H
0.1
1778
|
L
 -100.0%
H
0.1
38670000
|
L
H
0.1
75000000
|
L
H
0.1
75000000
|
| Gyre Therapeutics Inc |
|
779.3
|
7.4
|
L
 0.3%
H
7.1
7.4
|
L
 2.4%
H
6.8
7.6
|
L
 14.1%
H
6.3
7.6
|
L
 13.4%
H
5.6
7.6
|
L
 -0.3%
H
5.4
9.4
|
L
 -2%
H
5.4
130.5
|
L
 -2%
H
5.4
130.5
|
L
 -2%
H
5.4
130.5
|
| Korro Bio Inc |
|
140.9
|
9.6
|
L
H
9.4
9.6
|
L
 -18.9%
H
9.4
11.9
|
L
 -26.8%
H
9.4
15.2
|
L
 -30.5%
H
9.4
15.6
|
L
 -75.2%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Spyre Therapeutics Inc |
|
7,555.6
|
85.7
|
L
 -1.6%
H
85.6
88.1
|
L
 -7.5%
H
82.9
94.1
|
L
 -19.7%
H
82.9
110.2
|
L
 -0.6%
H
82.9
110.2
|
L
 404.1%
H
15.5
110.2
|
L
H
8.8
110.2
|
L
H
8.8
110.2
|
L
H
8.8
110.2
|
| Onconetix Inc |
|
4.5
|
1.0
|
L
 13.2%
H
1
1.4
|
L
 56.1%
H
0.6
1.4
|
L
 56.1%
H
0.6
1.4
|
L
 3%
H
0.6
1.4
|
L
 -99.4%
H
0.6
209.5
|
L
 -100.0%
H
0.6
102698.5
|
L
 -100.0%
H
0.6
15453000
|
L
 -100.0%
H
0.6
15453000
|
| Talphera Inc |
|
61.2
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 11.3%
H
1.0
1.5
|
L
 28.3%
H
0.7
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| Telomir Pharma Inc |
|
84.6
|
1.2
|
L
 1.7%
H
1.2
1.2
|
L
 9.8%
H
1.1
1.3
|
L
 5.1%
H
1.1
1.3
|
L
H
0.9
1.4
|
L
 -19.1%
H
0.9
2.1
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
| Skye Bioscience Inc |
|
7.4
|
1.7
|
L
 -1.8%
H
1.6
1.8
|
L
 6.4%
H
1.6
2.0
|
L
 -23.0%
H
1.5
2.3
|
L
 -69.2%
H
1.5
7.0
|
L
 -94.2%
H
1.5
39.9
|
L
H
1.5
57.2
|
L
H
1.5
57.2
|
L
H
1.5
57.2
|
| Alumis Inc |
|
919.0
|
7.1
|
L
 -2.6%
H
7.0
7.4
|
L
 -9.2%
H
7.0
8.1
|
L
 -69.2%
H
7.0
24.1
|
L
 -71.4%
H
7.0
31.4
|
L
 71.5%
H
3.8
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
| Actuate Therapeutics Inc |
|
16.3
|
0.7
|
L
 9.7%
H
0.6
0.8
|
L
 -32%
H
0.6
1.0
|
L
 -44.7%
H
0.6
2.0
|
L
 -65.1%
H
0.6
2.0
|
L
 -90.3%
H
0.6
8.5
|
L
H
0.6
12.0
|
L
H
0.6
12.0
|
L
H
0.6
12.0
|
| Bicara Therapeutics Inc |
|
1,271.2
|
19.2
|
L
 -2.9%
H
19.2
19.9
|
L
 -15.0%
H
19.2
23.3
|
L
 -18.5%
H
19.2
25.2
|
L
 -25.1%
H
19.2
31.0
|
L
 71.7%
H
10.5
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
| Gelteq Ltd |
|
5.9
|
0.6
|
L
H
0.5
0.6
|
L
 -5.2%
H
0.4
1.0
|
L
 3.8%
H
0.4
1.1
|
L
 -20.3%
H
0.4
1.1
|
L
 -62.1%
H
0.4
2.0
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
| Atlantic Intl Corp |
|
27.6
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 -29.2%
H
0.3
0.5
|
L
 -48.5%
H
0.3
0.8
|
L
 -56.4%
H
0.3
1.2
|
L
 -91.9%
H
0.3
4.6
|
L
 -86.9%
H
0.3
5.3
|
L
 -86.9%
H
0.3
5.3
|
L
 -86.9%
H
0.3
5.3
|
| BeiGene Ltd (ADR) |
|
40,820.1
|
360.9
|
L
 0.2%
H
358.5
365
|
L
 2.1%
H
348.8
368.3
|
L
 -3.0%
H
337.0
380
|
L
 30.2%
H
272.8
380
|
L
 9.4%
H
254.0
385.2
|
L
 95.4%
H
172.7
385.2
|
L
 95.4%
H
172.7
385.2
|
L
 95.4%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
3.5
|
2.7
|
L
 -7.3%
H
2.7
3.0
|
L
 -11.3%
H
2.7
3.7
|
L
 -52.8%
H
2.7
5.7
|
L
 968%
H
0.1
11.2
|
L
 90.7%
H
0.1
11.2
|
L
 360.3%
H
0.1
11.2
|
L
 360.3%
H
0.1
11.2
|
L
 360.3%
H
0.1
11.2
|
| Ascentage Pharma Grp Intl (ADR) |
|
1,387.8
|
14.9
|
L
 -2.4%
H
14.8
15.0
|
L
 -3.3%
H
14.8
16.2
|
L
 -11.1%
H
14.8
18.7
|
L
 -13%
H
14.8
20.4
|
L
 -60.3%
H
14.8
40.5
|
L
 -14.5%
H
14.8
48.5
|
L
 -14.5%
H
14.8
48.5
|
L
 -14.5%
H
14.8
48.5
|
| Maze Therapeutics Inc |
|
1,447.1
|
26.1
|
L
 -0.6%
H
25.4
27.8
|
L
 11.1%
H
22.0
29.9
|
L
 -12.0%
H
22.0
30.8
|
L
 -2.3%
H
22.0
33.5
|
L
 -0.5%
H
22.0
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
110.7
|
5.1
|
L
 -8.8%
H
5.0
5.6
|
L
 -8.5%
H
5.0
5.8
|
L
 -26.5%
H
4.5
7.3
|
L
 2.0%
H
4.5
8.1
|
L
 -58.4%
H
3.4
17.9
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
13.1
|
1.9
|
L
 -1.6%
H
1.8
1.9
|
L
 8.1%
H
1.7
2
|
L
 -31.5%
H
1.4
3.4
|
L
 -67.4%
H
1.4
8.3
|
L
 -77.5%
H
1.4
14.8
|
L
H
1.4
76
|
L
H
1.4
76
|
L
H
1.4
76
|
| Jyong Biotech Ltd |
|
150.7
|
2.0
|
L
 -5.6%
H
2.0
2.3
|
L
 -2.4%
H
2.0
2.4
|
L
 -8.6%
H
2.0
2.4
|
L
 16.7%
H
1.8
2.8
|
L
 -96.4%
H
1.4
63
|
L
 -79.9%
H
1.4
67
|
L
 -79.9%
H
1.4
67
|
L
 -79.9%
H
1.4
67
|
| LB Pharmaceuticals Inc |
|
1,204.2
|
37.3
|
L
 -1.2%
H
37.0
38.6
|
L
 -11.4%
H
37.0
43.4
|
L
 -22.6%
H
37.0
50.2
|
L
 22.5%
H
29.4
50.2
|
L
 148.9%
H
13.4
50.2
|
L
 115.8%
H
13.4
50.2
|
L
 115.8%
H
13.4
50.2
|
L
 115.8%
H
13.4
50.2
|
| Black Titan Corp |
|
6.8
|
0.5
|
L
 -7.4%
H
0.5
0.6
|
L
 31.6%
H
0.4
1.0
|
L
 -12.3%
H
0.3
1.0
|
L
 -37.5%
H
0.3
1.1
|
L
 -97.9%
H
0.3
23.5
|
L
 -97.9%
H
0.3
23.5
|
L
 -97.9%
H
0.3
23.5
|
L
 -97.9%
H
0.3
23.5
|
| Turn Therapeutics Inc |
|
379.3
|
12.5
|
L
 -5.8%
H
12.3
13.7
|
L
 -9.6%
H
12.1
16.5
|
L
 29.0%
H
9
16.5
|
L
 105.1%
H
5.8
16.5
|
L
 78.4%
H
2.6
26.5
|
L
 78.4%
H
2.6
26.5
|
L
 78.4%
H
2.6
26.5
|
L
 78.4%
H
2.6
26.5
|
| MapLight Therapeutics Inc |
|
581.3
|
10.5
|
L
 -2.8%
H
10.4
10.9
|
L
 -7.6%
H
10.1
11.3
|
L
 -7.9%
H
10.1
14.2
|
L
 -65.9%
H
9.1
40.4
|
L
 -43.0%
H
9.1
40.4
|
L
 -43.0%
H
9.1
40.4
|
L
 -43.0%
H
9.1
40.4
|
L
 -43.0%
H
9.1
40.4
|
| NovaBridge Biosciences ADR |
|
159.6
|
1.4
|
L
 -4.8%
H
1.3
1.4
|
L
 -15.3%
H
1.3
1.7
|
L
 -27.0%
H
1.3
2.0
|
L
 -13.8%
H
1.3
2.3
|
L
 -69.7%
H
1.3
5.2
|
L
 -69.7%
H
1.3
5.2
|
L
 -69.7%
H
1.3
5.2
|
L
 -69.7%
H
1.3
5.2
|
| Evommune Inc |
|
308.1
|
8.5
|
L
 -3.5%
H
8.3
8.8
|
L
 -9.4%
H
8.3
9.9
|
L
 -37.9%
H
8.3
14.4
|
L
 -64.0%
H
8.3
25.9
|
L
 -58.0%
H
8.3
33.2
|
L
 -58.0%
H
8.3
33.2
|
L
 -58.0%
H
8.3
33.2
|
L
 -58.0%
H
8.3
33.2
|
| Aktis Oncology Inc |
|
-
|
19.4
|
L
 -1.0%
H
19.0
19.8
|
L
 -15%
H
19.0
23.1
|
L
 -25.2%
H
19.0
27.7
|
L
 -32.3%
H
19.0
34.2
|
L
 -13.3%
H
14.7
34.2
|
L
 -13.3%
H
14.7
34.2
|
L
 -13.3%
H
14.7
34.2
|
L
 -13.3%
H
14.7
34.2
|
| Helus Pharma Inc |
|
921.4
|
12.6
|
L
 0.2%
H
12.5
12.9
|
L
 -10.1%
H
12.1
15.2
|
L
 -3.2%
H
11.3
15.2
|
L
 147.7%
H
5.1
15.2
|
L
 67.5%
H
3.8
15.2
|
L
 67.5%
H
3.8
15.2
|
L
 67.5%
H
3.8
15.2
|
L
 67.5%
H
3.8
15.2
|
| NervGen Pharma Corp |
|
208.6
|
1.9
|
L
 -4.0%
H
1.9
2.0
|
L
 -14.5%
H
1.9
2.3
|
L
 -3%
H
1.9
2.4
|
L
 -2.5%
H
1.6
2.4
|
L
 -66.3%
H
1.6
5.9
|
L
 -66.3%
H
1.6
5.9
|
L
 -66.3%
H
1.6
5.9
|
L
 -66.3%
H
1.6
5.9
|
| Veradermics Inc |
|
4,870.3
|
116.6
|
L
 0.7%
H
113.9
118.2
|
L
 7.3%
H
104.5
122
|
L
 18.4%
H
95.4
122
|
L
 -0.6%
H
93.8
131.2
|
L
 208.8%
H
35.1
131.2
|
L
 208.8%
H
35.1
131.2
|
L
 208.8%
H
35.1
131.2
|
L
 208.8%
H
35.1
131.2
|
| Eikon Therapeutics Inc |
|
429.0
|
7.9
|
L
 -4.5%
H
7.9
8.5
|
L
 -7.9%
H
7.7
9.3
|
L
 -29.0%
H
7.7
13
|
L
 -17.8%
H
7.7
14.5
|
L
 -47.2%
H
7.7
16.5
|
L
 -47.2%
H
7.7
16.5
|
L
 -47.2%
H
7.7
16.5
|
L
 -47.2%
H
7.7
16.5
|
| Satellos Bioscience Inc |
|
184.6
|
8.7
|
L
 -0.1%
H
8.5
8.9
|
L
 -10.1%
H
8.4
9.8
|
L
 -8.1%
H
8.4
10.5
|
L
 54.8%
H
5.7
10.7
|
L
 -22.7%
H
5.4
13.4
|
L
 -22.7%
H
5.4
13.4
|
L
 -22.7%
H
5.4
13.4
|
L
 -22.7%
H
5.4
13.4
|
| Avalyn Pharma Inc |
|
1,244.9
|
28.1
|
L
 -1.7%
H
27
28.5
|
L
 -16%
H
27
34.0
|
L
 -25.5%
H
27
39.1
|
L
 -6.7%
H
24.9
40.2
|
L
 -4.8%
H
24.2
40.2
|
L
 -4.8%
H
24.2
40.2
|
L
 -4.8%
H
24.2
40.2
|
L
 -4.8%
H
24.2
40.2
|
| Seaport Therapeutics Inc |
|
1,152.0
|
21.5
|
L
 1.9%
H
21.5
22.4
|
L
 -1.4%
H
19.9
23.1
|
L
 -10.6%
H
19.9
28.4
|
L
 11.4%
H
17.9
28.4
|
L
 8.5%
H
14.9
28.4
|
L
 8.5%
H
14.9
28.4
|
L
 8.5%
H
14.9
28.4
|
L
 8.5%
H
14.9
28.4
|
| Palatin Technologies Inc |
|
-
|
10.1
|
L
 2.8%
H
9.5
10.4
|
L
 -3.2%
H
9.5
11.7
|
L
 -0.6%
H
9.2
14
|
L
 -4.7%
H
7.2
14
|
L
 -28.6%
H
7.2
14.8
|
L
 -28.6%
H
7.2
14.8
|
L
 -28.6%
H
7.2
14.8
|
L
 -28.6%
H
7.2
14.8
|
| Parabilis Medicines Inc |
|
3,854.2
|
31.2
|
L
 -3.9%
H
29.6
32.3
|
L
 -23.7%
H
29.6
42.5
|
L
 -18.8%
H
29.6
42.5
|
L
 14.2%
H
25.7
42.5
|
L
 -1.3%
H
24.5
42.5
|
L
 -1.3%
H
24.5
42.5
|
L
 -1.3%
H
24.5
42.5
|
L
 -1.3%
H
24.5
42.5
|
| Vicore Pharma Holding AB ADR |
|
271.7
|
9.7
|
L
 -2.6%
H
9.6
9.8
|
L
 -7.2%
H
9.5
11.1
|
L
 -16.1%
H
9.5
13.2
|
L
 -30.0%
H
9.5
13.2
|
L
 -30.0%
H
9.5
13.2
|
L
 -30.0%
H
9.5
13.2
|
L
 -30.0%
H
9.5
13.2
|
L
 -30.0%
H
9.5
13.2
|
| Clinuvel Pharmaceuticals |
|
283.9
|
5.6
|
L
 -2.6%
H
5.6
5.8
|
L
 -3.9%
H
5.6
6.1
|
L
 -24.1%
H
5.6
8.1
|
L
 -19.0%
H
5.6
8.2
|
L
 -19.0%
H
5.6
8.2
|
L
 -19.0%
H
5.6
8.2
|
L
 -19.0%
H
5.6
8.2
|
L
 -19.0%
H
5.6
8.2
|
| Obsidian Therapeutics Inc |
|
794.4
|
12.9
|
L
 -4.1%
H
12.2
13.7
|
L
 -26.5%
H
12.2
18.2
|
L
 -31.2%
H
12.2
20.0
|
L
 -62.2%
H
12.2
39
|
L
 -62.2%
H
12.2
39
|
L
 -62.2%
H
12.2
39
|
L
 -62.2%
H
12.2
39
|
L
 -62.2%
H
12.2
39
|